FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000

=> file uspatfull

=> s mch or melanocyte concentrating hormone

571 MCH
752 MELANOCYTE
31634 CONCENTRATING
19149 HORMONE
1 MELANOCYTE CONCENTRATING HORMONE
(MELANOCYTE(W)CONCENTRATING(W)HORMONE)
L1 571 MCH OR MELANOCYTE CONCENTRATING HORMONE

=> s l1 and antagoni?

26360 ANTAGONI?
L2 45 L1 AND ANTAGONI?

=> s l2 and weight

859860 WEIGHT
L3 44 L2 AND WEIGHT

=> s l3 and eat? or appetite

18954 EAT?
3116 APPETITE
L4 3120 L3 AND EAT? OR APPETITE

=> s l3 and (eat? or appetite)

18954 EAT?
3116 APPETITE
L5 7 L3 AND (EAT? OR APPETITE)

=> d 1-7

L5 ANSWER 1 OF 7 USPATFULL
AN 2000:57883 USPATFULL
TI Agouti-related proteins
IN Stark, Kevin Lee, Newbury Park, CA, United States
Luethy, Roland, Newbury Park, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6060589 20000509
AI US 1998-33275 19980302 (9)
RLI Division of Ser. No. US 1996-757541, filed on 27 Nov 1996, now patented,
Pat. No. US 5766877
PRAI US 1996-17505 19960510 (60)
DT Utility
LN.CNT 1734
INCL INCLM: 530/350.000
INCLS: 530/300.000; 435/069.100
NCL NCLM: 530/350.000
NCLS: 435/069.100; 530/300.000
IC [7]
ICM: C07K014-435
EXF 530/350; 530/300; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 7 USPATFULL
AN 2000:17822 USPATFULL
TI Treatment methods using homeopathic preparations of growth factors
IN Brewitt, Barbara A., 5557 36.sup.th Ave. NE., Seattle, WA, United States 98105
PI US 6024734 20000215
AI US 1997-855096 19970513 (8)
RLI Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 which is a continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned
DT Utility
LN.CNT 2005
INCL INCLM: 604/500.000
INCLS: 604/890.100; 514/002.000; 514/009.000; 514/019.000; 530/351.000;
530/303.000
NCL NCLM: 604/500.000
NCLS: 514/002.000; 514/009.000; 514/019.000; 530/303.000; 530/351.000;
604/890.100
IC [7]
ICM: A61M031-00
EXF 604/500; 604/890.1; 604/501; 604/502; 604/503; 604/504; 604/505; 604/514; 604/530

L5 ANSWER 3 OF 7 USPATFULL
AN 1999:170609 USPATFULL
TI Inhibitors of interleukin-1.beta. converting enzyme
IN Batchelor, Mark James, Cumnor Hill, United Kingdom
Bebbington, David, Pewsey, United Kingdom
Bemis, Guy W., Arlington, MA, United States
Fridman, Wolf Herman, Paris, France
Gillespie, Roger John, Nr. Malmesbury, United Kingdom
Golec, Julian M. C., Swindon, United Kingdom
Lauffer, David J., Stow, MA, United States
Livingston, David J., Newtonville, MA, United States
Matharu, Saroop Singh, Cricklade, United Kingdom
Mullican, Michael D., Needham, MA, United States
Murcko, Mark A., Holliston, MA, United States
Murdoch, Robert, Highworth, United Kingdom
Zelle, Robert E., Stow, MA, United States
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 6008217 19991228
AI US 1995-575641 19951220 (8)
DT Utility
LN.CNT 5446
INCL INCLM: 514/221.000
INCLS: 540/500.000
NCL NCLM: 514/221.000
NCLS: 540/500.000
IC [6]
ICM: C07D217-22
ICS: C07D217-16; A61K031-47
EXF 514/221; 540/500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL
AN 1999:128543 USPATFULL
TI Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
IN Karanewsky, Donald S., Escondido, CA, United States
Linton, Steven D., San Diego, CA, United States
PA Idun Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
PI US 5968927 19991019
AI US 1997-928990 19970912 (8)
RLI Continuation-in-part of Ser. No. US 1996-710621, filed on 20 Sep 1996, now abandoned
DT Utility
LN.CNT 2053
INCL INCLM: 514/214.000
INCLS: 540/520.000
NCL NCLM: 514/079.000
NCLS: 514/212.050; 540/520.000
IC [6]

ICM: C07D487-06
ICS: A61K031-55
EXF 540/520; 514/214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 7 USPATFULL
AN 1999:63303 USPATFULL
TI Combination therapy for the treatment of diabetes and obesity
IN Smith, Roy G., Westfield, NJ, United States
Cascieri, Margaret A., East Windsor, NJ, United States
MacIntyre, Euan, Scotch Plains, NJ, United States
MacNeil, Douglas J., Westfield, NJ, United States
Menke, John G., Morganville, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5908830 19990601
AI US 1997-961749 19971030 (8)
PRAI US 1996-29233 19961031 (60)
DT Utility
LN.CNT 1080
INCL INCLM: 514/012.000
INCLS: 530/324.000; 530/350.000; 514/312.000; 424/309.000
NCL NCLM: 514/012.000
NCLS: 514/312.000; 530/324.000; 530/350.000
IC [6]
ICM: A61K038-00
ICS: A61K031-24; C07K005-00; C07K016-00
EXF 530/350; 530/324; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL
AN 1998:157312 USPATFULL
TI Promotion of ***eating*** behavior
IN Maratos-Flier, Eleftheria, Newton, MA, United States
PA Joslin Diabetes Center, Inc., Boston, MA, United States (U.S. corporation)
PI US 5849708 19981215
AI US 1995-473022 19950606 (8)
DT Utility
LN.CNT 2285
INCL INCLM: 514/013.000
INCLS: 530/300.000; 530/317.000
NCL NCLM: 514/013.000
NCLS: 530/300.000; 530/317.000
IC [6]
ICM: A61K038-00
EXF 530/300; 530/350; 530/317; 514/12; 514/14; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 USPATFULL
AN 1998:68802 USPATFULL
TI Genes encoding art, an agouti-related transcript
IN Stark, Kevin Lee, Newbury Park, CA, United States
Luethy, Roland, Newbury Park, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 5766877 19980616
AI US 1996-757541 19961127 (8)
PRAI US 1996-17505 19960510 (60)
DT Utility
LN.CNT 1681
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500
IC [6]
ICM: C12N015-12
EXF 435/69.1; 435/325; 435/320.1; 435/252.3; 435/254.11; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 5 kwic

L5 ANSWER 5 OF 7 USPATFULL
AB . . . a metabolic rate modifying agent (e.g., a .beta..sub.3 adrenergic receptor agonist) and a feeding behavior modifying agent (e.g., a NPY5 ***antagonist***) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients. Methods of. . .
SUMM Obesity, which can be defined as a body ***weight*** more than 20%
above the ideal body ***weight*** , is a major health concern in Western societies, since it is accompanied by numerous complications such as hypertension, non-insulin dependent. . . as a consequence of increased ratio of caloric intake to energy expenditure. The molecular factors regulating food intake and body ***weight*** balance are incompletely understood. [B. Staels et al., J. Biol. Chem. 270(27), 15958 (1995); F. Lonnquist et al., Nature Medicine. . .
SUMM . . . Chinese hamster ovary cells. See Emorine et al, Science, 1989, 245:1118-1121; and Liggett, Mol. Pharmacol., 1992, 42:634-637. The agonist and ***antagonist*** effects of the various compounds on the cultivated cells provide an indication of the antiobesity and antidiabetic effects of the. . .
SUMM . . . protein (also known as leptin), a 167 amino acid polypeptide, has been shown to result in a dose- and time-dependent ***weight*** loss when administered to mice via intraperitoneal (IP) injection. [M. A. Pelleymounter et al., Science 269, 540 (1995)]. This ***weight*** loss effect is attributable to both a reduction in food intake and an increase in energy expenditure. Moreover, since both. . .
SUMM . . . system, is another agent which has been identified as being connected with feeding behavior. Neuropeptide Y is involved in regulating ***eating*** behavior and is an extremely potent orixigenic agent [See e.g., Stanley, B. G., et al., Peptides 13: 581-587 (1992); Sahu,. . . In Endocrinology And Metabolism 4(7): 217-224 (1993)]. When administered intracerebroventricularly or injected into the hypothalamic paraventricular nucleus (PVN) it elicits ***eating*** in satiated rats [Clark, J. T., et al., Endocrinology 115(1): 427-429 (1984); Stanley, B. G. and S. F. Leibowitz, Proc.. . . Stanley, B. G. and S. F. Leibowitz, Life Sci. 35(26): 2635-42 (1984)] and intraventricular injection of antisera to NPY decreases ***eating*** [Stanley, B. G., et al., Peptides, supra; Sahu, A. and S. P. Kalra, supra]. It has been shown to stimulate ***appetite*** in a variety of species and at different stages of development [Stanley, B. G., Neuropeptide Y in multiple hypothalamic sites controls ***eating*** behavior, endocrine, and autonomic systems for body energy balance, in Neuropeptide Y, W. F. Colmers and C. Wahlestedt, Editor. 1993,. . .
SUMM . . . Jun. 6, 1996], it has now been found that the other subtypes (e.g., NPY1, NPY4) may also be involved in ***weight*** control, for example by effects on metabolic rate.
SUMM The hypothalamus plays a central role in the integrated regulation of energy homeostasis and body ***weight*** , and a number of hypothalamic neuropeptides, for example NPY, galanin, corticotrophin releasing factor (CRF), have been implicated in the mediation of these effects. Additionally, when melanin-concentrating hormone (***MCH***) was injected into the lateral ventricles of rats, their food consumption increased suggesting that ***MCH*** participates in the hypothalamic regulation of feeding behavior; this increase in food consumption was similar to that seen after galanin. . .
SUMM . . . a result of abnormal control of feeding behavior, thereby establishing a role for this receptor in the serotonergic control of ***appetite*** . [L. H. Tecott et al., Nature 374: 542-546 (1995)]. A 5-HT.sub.2C agonists would therefore be useful for inhibiting food intake.. . .
SUMM . . . fats, provides effective therapy for treating obesity and diabetes. More specifically, a combination of a .beta..sub.3 agonist and a NPY5 ***antagonist*** is particularly preferred for the treatment of obesity and diabetes.
SUMM (a) the metabolic rate modifying agent is selected from a .beta..sub.3 agonist, leptin, or a derivative thereof, a NPY1 ***antagonist*** , a NPY4 ***antagonist*** , a UCP1, UCP2 or UCP3 activating agent, Ergoset, a CRF agonist, an agent that inhibits the activity of a

specific. . .

SUMM (b) the feeding behavior modifying agent is selected from a NPY5 ***antagonist*** , leptin or a derivative thereof, a serotonin reuptake inhibitor, a ***MCH*** ***antagonist*** , a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin ***antagonist*** , a CRF agonist, a urocortin agonist, a melanocortin agonist, an enterostatin agonist, a CCK agonist, Cimetidine, a CCK secretagogue, Ergoset. . . Sibutramine. Preferably, the metabolic rate modifying agent is selected from a .beta..sub.3 agonist, leptin, or a derivative thereof, a NPY1 ***antagonist*** , a NPY4 ***antagonist*** or a UCP1, UCP2 or UCP3 activating agent; and the feeding behavior modifying agent is selected from a NPY5 ***antagonist*** , leptin or a derivative thereof, a serotonin reuptake inhibitor, a ***MCH*** ***antagonist*** , a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin ***antagonist*** , a CRF agonist, a urocortin agonist, a melanocortin agonist or an enterostatin agonist.

SUMM In a subclass of the invention is the composition wherein the feeding behavior modifying agent is a NPY5 ***antagonist*** .

SUMM . . . the invention is the composition wherein the metabolic rate modifying agent is selected from a .beta..sub.3 agonist and a NPY1 ***antagonist*** . Preferably, the metabolic rate modifying agent is a .beta..sub.3 agonist. Most preferably, the metabolic rate modifying agent is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3-cyclopentylpropyl)-5-tetrazolon-1-yl]benzenesulfonamide; or. . .

SUMM An illustration of the invention is the composition wherein the metabolic rate modifying agent is a NPY1 ***antagonist*** .

SUMM Exemplifying the invention is the composition which comprises leptin, or

a derivative thereof, and a NPY5 ***antagonist*** ; and the pharmaceutically acceptable salts and esters thereof.

SUMM (a) the metabolic rate increasing agent is selected from a 3 agonist, leptin, or a derivative thereof, a NPY1 ***antagonist*** , a NPY4 ***antagonist*** or a UCP1, UCP2 or UCP3 activating agent; and

SUMM (b) the feeding behavior inhibiting agent is selected from a NPY5 ***antagonist*** , leptin or a derivative thereof, a serotonin reuptake inhibitor, a ***MCH*** ***antagonist*** , a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin ***antagonist*** , a CRF agonist, a urocortin agonist, or a CCK ***antagonist*** , a melanocortin agonist or an enterostatin agonist.

SUMM Preferably, the feeding behavior inhibiting agent is a NPY5 ***antagonist*** and the metabolic rate increasing agent is a selected from .beta..sub.3 agonist and a NPY ***antagonist*** . More preferably, the metabolic rate increasing agent is a .beta..sub.3 agonist. Most preferably, the metabolic rate increasing agent is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3-cyclopentylpropyl)-5-tetrazolon-1-yl]benzenesulfonamide.

SUMM . . . thereof, for the treatment of obesity and diabetes. Obesity and diabetes mellitus are often treated by encouraging patients to lose ***weight*** by reducing their food intake and by increasing their metabolic rate. However, agents that reduce feed intake (e.g., leptin, leptin agonists, 5-HT.sub.2A agonists, 5-HT.sub.2C agonists, serotonin reuptake inhibitors, NPY5 ***antagonists*** , CCK agonists, GLP-1 agonists, galanin ***antagonists*** , glucagon agonists, ***MCH*** agonists) often do not have sustained effects on ***weight*** reduction. Thus, it has now been found that combination treatment with an agent that reduces feed intake with an agent that increases metabolic rate (e.g., .beta..sub.3 selective agonist, NPY1 ***antagonist*** , leptin, leptin agonist, NPY4 ***antagonist***) is advantageous over treatment with either agent alone in the treatment of obesity and diabetes.

SUMM The term "selective," as used herein in reference to an agonist or ***antagonist*** of a specified receptor subtype, refers to an agonist or ***antagonist*** which binds to the specified receptor subtype with at least ten-fold greater affinity than it binds to other subtypes of. . .

SUMM . . . agent and a feeding behavior inhibiting agent. Most preferably, the combination comprises a selective .beta..sub.3 agonist and an NPY Y5 ***antagonist*** .

SUMM Examples of metabolic rate modifying agents include, but are not limited to, .beta..sub.3 agonists, NPY1 ***antagonists*** , NPY4 ***antagonists*** , leptin, leptin agonists, and uncoupling protein ("UCP") activating agents, specifically UCP1, UCP2 and/or UCP3 activating agents. Although leptin is typically. . .

SUMM . . . of identifying ligands which bind to the Y1 receptor are described in WO 93/09227, published May 13, 1993. Moreover, NPY1 ***antagonists*** and their use in the diagnosis and treatment of feeding disorders are described in WO 96/14307, published May 17, 1996. The NPY1 ***antagonist*** compounds described in WO 96/14307 are preferred as metabolic rate modifying agents in the compositions and methods of the present invention. Additional NPY Y1 ***antagonist*** compounds useful as metabolic rate modifying agents are described in U.S. Pat. No. 5,554,621, EP 0 747 356 A1, EP. . . and in WO 95/17960, published Jul. 6, 1995. Thus, one of ordinary skill in the art could readily identify NPY4 ***antagonists*** useful as metabolic rate modifying agents in the compositions and methods of the present invention.

SUMM . . . leptin agonists 5-HT.sub.2A agonists, 5-HT.sub.2C agonists, serotonin reuptake inhibitors (e.g., dexfenfluramine marketed under the brand name Redux by Servier/Interneuron), NPY5 ***antagonists*** , CCK agonists (e.g., FPL-15849: Fisons, Rhone-Poulenc Rorer), GLP-1 agonists, ***MCH*** agonists, galanin ***antagonists*** , glucagon agonists, Cimetidine (Tagamet, SmithKline Beecham), Ergoset, Subutramine, urocortin agonists [see, M. Spina, et al., Science, 273, Sep. 13, 1996,. . . Lin, L. et al., Peptides 1997, 18(5): 657-661, describing the effect of enterostatin in chronically reducing fat intake and body ***weight*** in rats]. Preferably the feeding behavior modifying agent is selected from a NPY5 ***antagonist*** or leptin, or a derivative thereof.

SUMM . . . Jun, 6, 1996. One of ordinary skill in the art, following the teaching of WO 96/16542, could readily identify NPY5 ***antagonist*** compounds useful in the compositions and methods of the present invention. NPY Y5 ***antagonists*** and their use in the diagnosis and treatment of feeding disorders are described in WO 97/19682, WO 97/20820, WO 97/20821,. . .

SUMM . . . or single combination forms. For example, in a two-component combination which is the .beta..sub.3 agonist, Compound A, and a NPY5 ***antagonist*** , treatment with the NPY5 ***antagonist*** can commence prior to, subsequent to or concurrent with commencement of treatment with Compound A. Furthermore, the term administering also encompasses the use of prodrugs of the .beta..sub.3 agonist and/or NPY5 ***antagonist*** which convert in vivo to a selective .beta..sub.3 agonist or NPY5 ***antagonist*** . The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the. . .

SUMM . . . compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the ***weight*** of the unit. The amount of active ingredients in such therapeutically useful compositions is such that an effective dosage will. . .

SUMM . . . utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, ***weight*** , sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the. . .

SUMM . . . rate modifying agent is administered at a daily dosage of from about 0.001 to about 20 mg/kg of animal body ***weight*** , preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . behavior modifying agent is administered at a daily dosage of from about 0.001 to about 20 mg/kg of animal body ***weight*** , preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . .

SUMM . . . is administered at a daily dosage of from about 0.001 milligram to about 20 milligram per kilogram of animal body ***weight*** , preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . release form. Preferably, the daily dosage of Ob protein is from about 0.05 mg/kg to about 5 mg/kg. The NPY5

antagonist is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY5 ***antagonist*** will generally be from about 0.07 milligrams to about 3500 milligrams. The NPY1 ***antagonist***

is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY1 ***antagonist*** will generally be from about 0.07 milligrams to about 3500 milligrams. The dosage regimen of any of the individual components. . . the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body ***weight*** , general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition,. . .

SUMM . . . A is administered at a daily dosage of from 0.01 milligram to about 20 milligrams per kilogram of animal body ***weight*** , preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . constant infusion. Preferably, the daily dosage of Ob protein is from about 0.05 mg/kg to about 5 mg/kg. The NPY5 ***antagonist*** is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY5 ***antagonist*** will generally be from about 0.07 milligrams to about 3500 milligrams. The NPY1 ***antagonist*** is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY1 ***antagonist*** will generally be from about 0.07 milligrams to about 3500 milligrams. The dosage regimen of any of the components of. . . the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body ***weight*** , general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition,. . .

DETD . . . g, horseradish peroxidase linked F(ab').sub.2 fragment, Amersham) was used at 1:3000 dilution. A single immunoreactive protein with an apparent molecular ***weight*** of 14.5 kDa was identified.

DETD . . . as a molecule that inhibits feed intake such as a selective serotonin 5HT2C receptor subtype agonist, an NPY5 selective receptor ***antagonist*** , a galanin ***antagonist*** , a CCK agonist, an ***MCH*** ***antagonist*** , a CRF agonist, a urocortin agonist, a glucagon-like peptide agonist, a glucagon agonist, leptin, leptin agonist. Compound C is a compound that increases metabolic rate such as a selective beta-3 adrenergic receptor agonist (e.g., Compound A), an NPY1 receptor ***antagonist*** , leptin, leptin agonist. Human patients are given by injection (i.e., subcutaneous, intramuscular or intravenous) or orally of 0.001 to 100. . . are treated daily for a six month period. A set of control patients are untreated (e.g., placebo) for comparison. Body ***weight*** data are collected each week and a sustained decrease in body ***weight*** of at least 2% is

<------User Break------>

u

=>

=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000

L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE
L2 45 S L1 AND ANTAGONI?
L3 44 S L2 AND WEIGHT
L4 3120 S L3 AND EAT? OR APPETITE
L5 7 S L3 AND (EAT? OR APPETITE)

=> s (mch or melanocyte concentrating hormone) (3a) antagonis? (3a) (weight or eat? or appetite)

571 MCH
752 MELANOCYTE
31634 CONCENTRATING
19149 HORMONE
1 MELANOCYTE CONCENTRATING HORMONE
(MELANOCYTE(W)CONCENTRATING(W)HORMONE)
25083 ANTAGONIS?
859860 WEIGHT
18954 EAT?
3116 APPETITE
L6 0 (MCH OR MELANOCYTE CONCENTRATING HORMONE) (3A) ANTAGONIS? (3A)
(WEIGHT OR EAT? OR APPETITE)

=> s (mch or melanocyte concentrating hormone) p antagonis? p (weight or eat? or appetite)

MISSING OPERATOR HORMONE) P ANTAGONIS
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000
L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE
L2 45 S L1 AND ANTAGONI?
L3 44 S L2 AND WEIGHT
L4 3120 S L3 AND EAT? OR APPETITE
L5 7 S L3 AND (EAT? OR APPETITE)
L6 0 S (MCH OR MELANOCYTE CONCENTRATING HORMONE) (3A) ANTAGONIS? (3A

=> s l1 p l2 p (weight or appetite)

MISSING OPERATOR L1 P L2
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 (5a) l2 (5a) (weight or appetite)

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (5A) L2'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L2 (5A) '
859860 WEIGHT
3116 APPETITE
L7 44 L1 (5A) L2 (5A) (WEIGHT OR APPETITE)

=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000
L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE
L2 45 S L1 AND ANTAGONI?
L3 44 S L2 AND WEIGHT
L4 3120 S L3 AND EAT? OR APPETITE
L5 7 S L3 AND (EAT? OR APPETITE)
L6 0 S (MCH OR MELANOCYTE CONCENTRATING HORMONE) (3A) ANTAGONIS? (3A
L7 44 S L1 (5A) L2 (5A) (WEIGHT OR APPETITE)

=> s l7 not l5

L8 37 L7 NOT L5

=> d 1-

YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE?
Y/(N):y

L8 ANSWER 1 OF 37 USPATFULL
AN 2000:84319 USPATFULL

TI Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors
IN Allen, Hamish John, Boylston, MA, United States
Brady, Kenneth Dale, Worcester, MA, United States
Harter, William Glen, Chelsea, MI, United States
Lunney, Elizabeth Ann, Ann Arbor, MI, United States
Plummer, Mark Stephen, Dexter, MI, United States
Sawyer, Tomi, Southborough, MA, United States
Shahripour, Aurash, Ann Arbor, MI, United States
Walker, Nigel, Dossenheim, Germany, Federal Republic of
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 6083981 20000704
WO 9816504 19980423
AI US 1999-284425 19990409 (9)
WO 1997-US18406 19971009
19990409 PCT 371 date
19990409 PCT 102(e) date
PRAI US 1996-28323 19961011 (60)
DT Utility
LN.CNT 1419
INCL INCLM: 514/471.000
INCLS: 549/479.000; 549/528.000; 549/562.000; 549/563.000; 560/012.000;
560/013.000; 562/430.000
NCL NCLM: 514/471.000
NCLS: 549/479.000; 549/528.000; 549/562.000; 549/563.000; 560/012.000;
560/013.000; 562/430.000
IC [7]
ICM: A61K031-341
ICS: C07D307-40
EXF 514/528; 514/562; 514/563; 514/471; 560/12; 560/13; 562/430; 549/479
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 37 USPATFULL
AN 2000:77037 USPATFULL
TI Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
IN Storkus, Walter J., Glenshaw, PA, United States
Lotze, Michael T., Pittsburgh, PA, United States
PA University of Pittsburgh, Pittsburgh, PA, United States (U.S. corporation)
PI US 6077519 20000620
AI US 1997-785831 19970115 (8)
RLI Continuation-in-part of Ser. No. US 1995-474120, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1993-11007, filed on 29 Jan 1993, now abandoned
DT Utility
LN.CNT 3161
INCL INCLM: 424/277.100
INCLS: 424/085.100; 424/093.710; 435/070.100; 435/070.300; 435/325.000;
435/372.000; 435/384.000; 435/385.000; 435/386.000; 514/002.000;
514/021.000; 530/344.000
NCL NCLM: 424/277.100
NCLS: 424/085.100; 424/093.710; 435/070.100; 435/070.300; 435/325.000;
435/372.000; 435/384.000; 435/385.000; 435/386.000; 514/002.000;
514/021.000; 530/344.000
IC [7]
ICM: A61K035-12
ICS: A61K038-00; C12N015-85; C07K005-00
EXF 424/277.1; 424/85.1; 424/93.71; 435/70.1; 435/70.3; 435/325; 435/372;
435/384; 435/385; 435/386; 514/2; 514/21; 530/344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 37 USPATFULL
AN 2000:47216 USPATFULL
TI Cloning and characterizing of genes associated with long-term memory
IN Tully, Timothy P., Cold Spring Harbor, NY, United States
Yin, Jerry Chi-Ping, Huntington, NY, United States
PA Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States (U.S. corporation)
PI US 6051559 20000418
AI US 1994-361063 19941221 (8)
RLI Continuation-in-part of Ser. No. US 1994-319866, filed on 7 Oct 1994
DT Utility
LN.CNT 4642
INCL INCLM: 514/044.000
INCLS: 514/002.000; 424/130.100
NCL NCLM: 514/044.000
NCLS: 424/130.100; 514/002.000
IC [7]
ICM: A61K039-395
ICS: A01N037-18; A01N043-04
EXF 536/23.1; 514/44; 514/2; 424/93.1; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 37 USPATFULL
AN 2000:44136 USPATFULL
TI Lipoxin compounds and their use in treating cell proliferative disorders
IN Serhan, Charles N., Wellesley, MA, United States
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6048897 20000411
AI US 1996-712610 19960913 (8)
RLI Continuation-in-part of Ser. No. US 1995-453125, filed on 31 May 1995, now patented, Pat. No. US 5648512 which is a division of Ser. No. US 1994-260030, filed on 15 Jun 1994, now patented, Pat. No. US 5441951, issued on 15 Aug 1995 which is a continuation-in-part of Ser. No. US 1993-77300, filed on 15 Jun 1993, now abandoned
DT Utility
LN.CNT 2924
INCL INCLM: 514/560.000
INCLS: 562/586.000; 562/598.000; 562/600.000
NCL NCLM: 514/560.000
NCLS: 562/586.000; 562/598.000; 562/600.000
IC [7]
ICM: A01N037-00
ICS: C07C059-00; C07C057-02; C07C051-42
EXF 562/586; 562/598; 562/600; 514/560
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 37 USPATFULL
AN 2000:27584 USPATFULL
TI Cystic fibrosis therapy
IN Mrsny, Randall J., Redwood City, CA, United States
Shen, Ben-Quan, San Francisco, CA, United States
Widdicombe, Jonathan H., Lafayette, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
Children's Hospital Medical Center of Northern California, Oakland, CA, United States (U.S. corporation)
PI US 6033688 20000307
AI US 1997-923754 19970902 (8)
RLI Division of Ser. No. US 1996-713048, filed on 12 Sep 1996, now patented,
Pat. No. US 5855918
PRAI US 1995-3581 19950912 (60)
US 1996-10509 19960124 (60)
DT Utility
LN.CNT 873
INCL INCLM: 424/530.000
INCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000
NCL NCLM: 424/530.000
NCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000
IC [7]

ICM: A61K035-16
EXF 514/2; 514/21; 424/529; 424/530; 424/531; 424/532

L8 ANSWER 6 OF 37 USPATFULL
AN 1999:85574 USPATFULL
TI Cloning and characterizing of genes associated with long-term memory
IN Tully, Timothy P., Cold Spring Harbor, NY, United States
Yin, Jerry Chi-Ping, Huntington, NY, United States
Regulski, Michael, Huntington, NY, United States
PA Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States (U.S. corporation)
PI US 5929223 19990727
AI US 1994-319866 19941007 (8)
DT Utility
LN.CNT 3318
INCL INCLM: 536/023.500
INCLS: 536/023.100
NCL NCLM: 536/023.500
NCLS: 536/023.100
IC [6]
ICM: C07H021-04
EXF 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 37 USPATFULL
AN 1999:75646 USPATFULL
TI Hydroxamate inhibitors of interleukin-1.beta. converting enzyme
IN Allen, Hamish John, Shrewsbury, MA, United States
Brady, Kenneth Dale, Worcester, MA, United States
Caprathe, Bradley William, Livonia, MI, United States
Galatsis, Paul, Ann Arbor, MI, United States
Gilmore, John Lodge, Ann Arbor, MI, United States
Hays, Sheryl Jeanne, Ann Arbor, MI, United States
Talanian, Robert Vincent, Harvard, MA, United States
Walker, Nigel, Dossenheim, Germany, Federal Republic of
Warmus, Joseph Scott, Ann Arbor, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
BASF Aktiengesellsschaft, Ludwigshafen, Germany, Federal Republic of (non-U.S. corporation)
PI US 5919790 19990706
AI US 1997-942605 19971002 (8)
PRAI US 1996-28324 19961011 (60)
DT Utility
LN.CNT 1124
INCL INCLM: 514/278.000
INCLS: 514/412.000; 514/416.000; 514/417.000; 514/418.000; 514/424.000;
514/425.000; 546/018.000; 546/122.000; 546/139.000; 546/249.000; 548/472.000; 548/475.000; 548/486.000; 548/512.000; 548/514.000; 548/530.000; 548/300.100; 548/146.000; 560/312.000; 562/444.000; 544/242.000; 549/029.000; 549/049.000; 549/434.000
NCL NCLM: 514/278.000
NCLS: 514/412.000; 514/416.000; 514/417.000; 514/418.000; 514/424.000;
514/425.000; 544/242.000; 546/018.000; 546/122.000; 546/139.000; 546/249.000; 548/146.000; 548/300.100; 548/472.000; 548/475.000; 548/486.000; 548/512.000; 548/514.000; 548/530.000; 549/029.000; 549/049.000; 549/434.000; 560/312.000; 562/444.000
IC [6]
ICM: A61K031-405
ICS: A61K031-44; C07C259-08; C07C229-32; C07D209-34; C07D209-46;
C07D209-48; C07D221-20
EXF 514/278; 514/412; 514/416; 514/417; 514/418; 514/424; 514/425; 546/18;
548/475; 548/486; 548/472; 548/514; 548/512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 37 USPATFULL
AN 1999:34025 USPATFULL
TI Compositions and methods for treating and preventing pathologies including cancer
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5883124 19990316
AI US 1995-484615 19950607 (8)
RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned
DT Utility
LN.CNT 7729
INCL INCLM: 514/538.000
INCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
514/725.000
NCL NCLM: 514/538.000
NCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
514/725.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 37 USPATFULL
AN 1999:27613 USPATFULL
TI Pharmaceutical compositions for the treatment or prevention of disorders in the eye
IN Naveh, Nava, Tel-Aviv, Israel
PA Ramot University Authority for Applied Research and Industrial Development Ltd., Tel-Aviv, Israel (non-U.S. corporation)
PI US 5877154 19990302
AI US 1995-570813 19951212 (8)
RLI Continuation of Ser. No. US 1993-38109, filed on 29 Mar 1993, now abandoned
PRAI IL 1992-101441 19920401
DT Utility
LN.CNT 660
INCL INCLM: 514/014.000
INCLS: 530/517.000
NCL NCLM: 514/014.000
NCLS: 530/327.000
IC [6]
ICM: A61K038-00
EXF 530/517; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 37 USPATFULL
AN 1999:24643 USPATFULL
TI Inhibitors of interleukin-1.beta. converting enzyme
IN Batchelor, Mark James, Cumnor Hill, United Kingdom
Bebbington, David, Pewsey, United Kingdom
Bemis, Guy W., Arlington, MA, United States
Fridman, Wolf Herman, Paris, France
Gillespie, Roger John, Oaksey, United Kingdom
Golec, Julian M. C., Ashbury, United Kingdom
Lauffer, David J., Stow, MA, United States
Livingston, David J., Newtonville, MA, United States
Matharu, Saroop Singh, Cricklade, United Kingdom
Mullican, Michael D., Needham, MA, United States
Murcko, Mark A., Holliston, MA, United States
Murdoch, Robert, Highworth, United Kingdom
Zelle, Robert E., Stow, MA, United States
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 5874424 19990223
AI US 1996-598332 19960208 (8)

RLI Continuation-in-part of Ser. No. US 1995-575641, filed on 20 Dec 1995
DT Utility
LN.CNT 7430
INCL INCLM: 514/221.000
INCLS: 514/211.000; 514/220.000; 540/491.000; 540/495.000; 540/500.000;
540/501.000
NCL NCLM: 514/221.000
NCLS: 514/211.000; 514/211.150; 514/217.030; 514/220.000; 540/491.000;
540/495.000; 540/500.000; 540/501.000
IC [6]
ICM: A61K031-55
ICS: C07D243-02
EXF 540/500; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 37 USPATFULL
AN 1999:1259 USPATFULL
TI Cystic fibrosis therapy
IN Mrsny, Randall J., Redwood City, CA, United States
Shen, Ben-Quan, San Francisco, CA, United States
Widdicombe, Jonathan H., Lafayette, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Children's Hospital Medical Center of Northern California, Oakland, CA, United States (U.S. corporation)
Regents of the University of CA, Oakland, CA, United States (U.S. corporation)
PI US 5855918 19990105
AI US 1996-713048 19960912 (8)
PRAI US 1995-3581 19950912 (60)
US 1996-10509 19960124 (60)
DT Utility
LN.CNT 874
INCL INCLM: 424/530.000
INCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000
NCL NCLM: 424/530.000
NCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000
IC [6]
ICM: A61K035-16
EXF 514/2; 514/21; 424/530; 424/531; 424/532

L8 ANSWER 12 OF 37 USPATFULL
AN 1998:159986 USPATFULL
TI Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5852056 19981222
WO 9510271 19950420
AI US 1996-633833 19960410 (8)
WO 1994-US11492 19941012
19960410 PCT 371 date
19960410 PCT 102(e) date
RLI Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12 Oct 1993, now patented, Pat. No. US 5635532 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned
DT Utility
LN.CNT 5051
INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCL NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-195; A61K031-24
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 37 USPATFULL
AN 1998:159748 USPATFULL
TI MCH4 and MCH5, apoptotic proteases
IN Alnemri, Emad S., Ambler, PA, United States
Fernandes-Alnemri, Teresa, Ambler, PA, United States
Litwack, Gerald, Wynnewood, PA, United States
Armstrong, Robert, San Diego, CA, United States
Tomaselli, Kevin, La Jolla, CA, United States
PA IDUN Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
PI US 5851815 19981222
AI US 1996-618408 19960319 (8)
DT Utility
LN.CNT 1800
INCL INCLM: 435/219.000
INCLS: 435/183.000; 435/212.000; 530/324.000
NCL NCLM: 435/219.000
NCLS: 435/183.000; 435/212.000; 530/324.000
IC [6]
ICM: C12N009-50
ICS: C12N009-48; A61K038-00
EXF 435/183; 435/212; 435/219; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 37 USPATFULL
AN 1998:157338 USPATFULL
TI Isoxazoline and isoxazole fibrinogen receptor ***antagonists***
IN Wityak, John, West Grove, PA, United States
Xue, Chu-Biao, Hockessin, DE, United States
Sielecki-Dzurdz, Thais Motria, Newark, DE, United States
Olson, Richard Eric, Wilmington, DE, United States
Degrado, William Frank, Moylan, PA, United States
Cain, Gary Avonn, Wilmington, DE, United States
Batt, Douglas Guy, Wilmington, DE, United States
Pinto, Donald, Newark, DE, United States
Hussain, Munir Alwan, Wilmington, DE, United States
Mousa, Shaker Ahmed, Lincoln University, PA, United States
PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States
(U.S. corporation)
PI US 5849736 19981215
AI US 1995-455436 19950531 (8)
RLI Continuation-in-part of Ser. No. US 1994-337920, filed on 10 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-232961, filed on 22 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-157598, filed on 24 Nov 1993, now abandoned
DT Utility
LN.CNT 11841
INCL INCLM: 514/227.800
INCLS: 514/236.800; 514/269.000; 514/307.000; 514/326.000; 514/340.000;
514/365.000; 514/378.000; 514/379.000; 514/380.000; 544/060.000; 544/111.000; 544/137.000; 544/140.000; 544/297.000; 544/298.000; 544/322.000; 544/333.000; 546/141.000; 546/143.000; 546/209.000; 546/275.000; 548/146.000; 548/240.000; 548/245.000; 548/248.000
NCL NCLM: 514/227.800
NCLS: 514/236.800; 514/269.000; 514/307.000; 514/310.000; 514/326.000;
514/340.000; 514/365.000; 514/378.000; 514/379.000; 514/380.000; 544/060.000; 544/111.000; 544/137.000; 544/140.000; 544/297.000; 544/298.000; 544/322.000; 544/333.000; 546/015.000; 546/141.000; 546/143.000; 546/209.000; 546/275.400; 548/146.000; 548/240.000; 548/245.000; 548/248.000
IC [6]

ICM: C07D261-02
ICS: C07D217-00; A61K031-54; A61K031-445
EXF 548/240; 548/248; 548/245; 548/146; 546/275; 546/204; 546/141; 546/143;
546/146; 544/137; 544/140; 544/111; 544/60; 544/297; 544/298; 544/322;
544/333; 514/326; 514/340; 514/378; 514/379; 514/380; 514/227.8; 514/236.8; 514/269; 514/307; 514/310; 514/365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 37 USPATFULL
AN 1998:150994 USPATFULL
TI Compositions and methods for treating and preventing pathologies including cancer
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represeneted by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5843994 19981201
AI US 1995-478264 19950607 (8)
RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,
Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned
DT Utility
LN.CNT 7935
INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCL NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
IC [6]
ICM: A61K031-21
ICS: A01N047-40
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 37 USPATFULL
AN 1998:150907 USPATFULL
TI Inhibitors of interleukin-1.beta.converting enzyme
IN Bemis, Guy W., Arlington, MA, United States
Duffy, John P., Brighton, MA, United States
Fridman, Wolf Herman, Paris, France
Golec, Julian M. C., Ashbury, United Kingdom
Livingston, David J., Newtonville, MA, United States
Mullican, Michael D., Needham, MA, United States
Murcko, Mark A., Holliston, MA, United States
Zelle, Robert E., Stow, MA, United States
PA Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5843904 19981201
AI US 1995-575648 19951220 (8)
DT Utility
LN.CNT 1826
INCL INCLM: 514/018.000
INCLS: 514/019.000; 530/331.000; 530/330.000
NCL NCLM: 514/018.000
NCLS: 514/019.000; 530/330.000; 530/331.000
IC [6]
ICM: A61K038-00
EXF 530/331; 530/330; 514/18; 514/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 37 USPATFULL
AN 1998:9533 USPATFULL
TI Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5712307 19980127
AI US 1995-465924 19950606 (8)
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4169
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 37 USPATFULL
AN 1998:7096 USPATFULL
TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia
IN Samid, Dvorit, Rockville, VA, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5710178 19980120
AI US 1995-469691 19950606 (8)
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4261
INCL INCLM: 514/557.000
INCLS: 514/568.000; 514/570.000
NCL NCLM: 514/557.000
NCLS: 514/568.000; 514/570.000
IC [6]
ICM: A01N037-00
ICS: A61K031-19
EXF 514/557; 514/568; 514/570; 562/405; 562/493; 562/511; 562/473; 562/490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 37 USPATFULL
AN 1998:4624 USPATFULL
TI Methods for promoting wound healing
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5708025 19980113
AI US 1995-465835 19950606 (8)
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4206
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000; 514/885.000; 514/886.000; 514/928.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000; 514/885.000; 514/886.000; 514/928.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/563; 514/567; 514/885; 514/886; 514/928; 560/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 37 USPATFULL
AN 97:76161 USPATFULL
TI Methods for treating neoplastic conditions using phenylacetic acid and

derivatives thereof
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5661179 19970826
AI US 1995-469466 19950606 (8)
RLI Continuation of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a
continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned
DT Utility
LN.CNT 4056
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000; 560/019.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000; 560/019.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44
EXF 514/538; 514/563; 514/567; 560/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 37 USPATFULL
AN 97:68500 USPATFULL
TI Methods for prevention of cancer using phenylacetic acids and derivatives thereof
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5654333 19970805
AI US 1995-465941 19950606 (8)
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4088
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 37 USPATFULL
AN 97:61839 USPATFULL
TI Lipoxin compounds
IN Serhan, Charles N., Boston, MA, United States
PA Brigham & Womens Hospital, Boston, MA, United States (U.S. corporation)
PI US 5648512 19970715
AI US 1995-453125 19950531 (8)
RLI Division of Ser. No. US 1994-260030, filed on 15 Jun 1994, now patented,
Pat. No. US 5441951 which is a continuation-in-part of Ser. No. US 1993-77300, filed on 15 Jun 1993, now abandoned
DT Utility
LN.CNT 2197
INCL INCLM: 560/009.000
INCLS: 560/019.000; 560/103.000; 560/187.000; 562/587.000
NCL NCLM: 560/009.000
NCLS: 560/019.000; 560/103.000; 560/187.000; 562/587.000
IC [6]
ICM: C07C321-08
ICS: C07C069-66; C07C059-105
EXF 560/103; 560/9; 560/19; 560/187; 562/587
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 37 USPATFULL
AN 97:47438 USPATFULL
TI Methods for inducing differentiation of a cell using phenyacetic acid and derivatives
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5635533 19970603
AI US 1995-470229 19950606 (8)
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4108
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 37 USPATFULL
AN 97:47437 USPATFULL
TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5635532 19970603
AI US 1993-135661 19931012 (8)
RLI Continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 4105
INCL INCLM: 514/538.000
INCLS: 514/563.000; 514/567.000; 560/019.000
NCL NCLM: 514/538.000
NCLS: 514/563.000; 514/567.000; 560/019.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-195; A61K031-24
EXF 514/538; 514/563; 514/567; 560/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 37 USPATFULL
AN 97:40765 USPATFULL
TI Homeopathic dilutions of growth factors
IN Brewitt, Barbara, 5557 - 36th Ave. NE., Seattle, WA, United States 98105-2313
PI US 5629286 19970513
AI US 1996-710040 19960910 (8)
RLI Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned
DT Utility
LN.CNT 1409
INCL INCLM: 514/002.000
INCLS: 530/351.000; 530/303.000
NCL NCLM: 514/002.000
NCLS: 530/303.000; 530/351.000
IC [6]
ICM: A01N037-18
EXF 604/890.1; 128/907; 530/350; 530/351; 530/300-303; 514/2; 514/3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 37 USPATFULL
AN 97:16085 USPATFULL
TI Compositions and methods for treating and preventing pathologies including cancer
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health

and Human Services, Washington, DC, United States (U.S. government)
PI US 5605930 19970225
AI US 1994-207521 19940307 (8)
RLI Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
DT Utility
LN.CNT 7722
INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCL NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
IC [6]
ICM: A61K031-21
ICS: A01N037-00; A01N047-40; A01N047-46
EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 37 USPATFULL
AN 96:72899 USPATFULL
TI Imidazole 5-position substituted angiotensin II ***antagonists***
IN Duncia, John J. V., Wilmington, DE, United States
Ensinger, Carol L., Newark, DE, United States
Olson, Richard E., Wilmington, DE, United States
Quan, Mimi L., Newark, DE, United States
Santella, III, Joseph B., Springfield, PA, United States
Vanatten, Mary K., Wilmington, DE, United States
PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States
(U.S. corporation)
PI US 5545651 19960813
AI US 1994-348843 19941128 (8)
RLI Division of Ser. No. US 1993-72977, filed on 10 Jun 1993, now patented, Pat. No. US 5395844
DT Utility
LN.CNT 5010
INCL INCLM: 514/381.000
INCLS: 514/235.800; 514/307.000; 514/314.000; 514/326.000; 514/333.000;
514/341.000; 514/359.000; 514/383.000; 514/397.000; 514/398.000;
514/399.000; 514/400.000; 544/139.000; 546/148.000; 546/174.000;
546/176.000; 546/180.000; 546/210.000; 546/256.000; 546/272.400;
546/272.700; 546/274.400; 546/274.700; 546/275.100; 546/022.000;
546/023.000; 546/024.000; 548/253.000; 548/255.000; 548/261.000;
548/266.200; 548/315.100; 548/335.100; 548/341.100; 548/343.100;
548/343.500; 548/346.100; 548/314.700
NCL NCLM: 514/381.000
NCLS: 514/235.800; 514/307.000; 514/314.000; 514/326.000; 514/333.000;
514/341.000; 514/359.000; 514/383.000; 514/397.000; 514/398.000;
514/399.000; 514/400.000; 544/139.000; 546/022.000; 546/023.000;
546/024.000; 546/148.000; 546/174.000; 546/176.000; 546/180.000;
546/210.000; 546/256.000; 546/272.400; 546/272.700; 546/274.400;
546/274.700; 546/275.100; 548/253.000; 548/255.000; 548/261.000;
548/266.200; 548/314.700; 548/315.100; 548/335.100; 548/341.100;
548/343.100; 548/343.500; 548/346.100
IC [6]
ICM: C07D401-14
ICS: A61K031-415
EXF 546/207; 546/210; 546/256; 546/276; 546/148; 546/180; 546/174; 546/176;
548/387; 548/253; 548/315.1; 548/319.7; 548/335.1; 548/341.1; 548/343.5;
548/346.1; 548/255; 548/261; 548/266.2; 548/343.1; 514/326; 514/333;
514/341; 514/381; 514/396; 514/398; 514/399; 514/400; 514/397;
514/235.8; 514/307; 514/314; 514/383; 514/359; 544/139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 37 USPATFULL
AN 96:55851 USPATFULL
TI Peptides of melanin concentrating hormone precursor
IN Vaughn, Joan, San Diego, CA, United States
Fischer, Wolfgang H., Solano Beach, CA, United States
Rivier, Jean E. F., La Jolla, CA, United States
Nahon, Jean-Louis M., San Diego, CA, United States
Presse, Francoise G., San Diego, CA, United States
Vale, Jr., Wylie W., La Jolla, CA, United States
PA The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)
PI US 5530095 19960625
AI US 1995-447613 19950523 (8)
RLI Division of Ser. No. US 1994-208531, filed on 9 Mar 1994, now patented,
Pat. No. US 5449766 which is a division of Ser. No. US 1991-733660, filed on 22 Jul 1991, now abandoned which is a division of Ser. No. US 1989-326984, filed on 22 Mar 1989, now patented, Pat. No. US 5049655
DT Utility
LN.CNT 1458
INCL INCLM: 530/326.000
INCLS: 530/327.000; 530/395.000; 435/069.400
NCL NCLM: 530/326.000
NCLS: 435/069.400; 530/327.000; 530/395.000
IC [6]
ICM: C07K007-08
ICS: C12P021-02
EXF 530/326; 530/327; 530/395; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 37 USPATFULL
AN 96:21081 USPATFULL
TI Platelet aggregation-inhibiting peptides
IN Sato, Yoshimi, Kawasaki, Japan
Hayashi, Yoshio, Kawasaki, Japan
Katada, Jun, Kawasaki, Japan
PA Nippon Steel Corporation, Tokyo, Japan (non-U.S. corporation)
PI US 5498601 19960312
WO 9405696 19940317
AI US 1994-232261 19940506 (8)
WO 1993-JP1262 19930907
19940506 PCT 371 date
19940506 PCT 102(e) date
PRAI JP 1992-238624 19920709
JP 1993-203962 19930818
DT Utility
LN.CNT 2230
INCL INCLM: 514/017.000
INCLS: 514/008.000; 530/322.000; 530/329.000; 530/330.000
NCL NCLM: 514/017.000
NCLS: 514/008.000; 530/322.000; 530/329.000; 530/330.000
IC [6]
ICM: A61K038-04
ICS: C07K007-00
EXF 530/322; 530/329; 530/330; 514/8; 514/17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 37 USPATFULL
AN 95:82360 USPATFULL
TI DNA encoding NEI and NGE peptides
IN Vaughan, Joan, San Diego, CA, United States
Fischer, Wolfgang H., Solano Beach, CA, United States
Rivier, Jean E. F., La Jolla, CA, United States
Nahon, Jean-Louis M., San Diego, CA, United States
Presse, Francoise G., San Diego, CA, United States
Vale, Jr., Wylie W., La Jolla, CA, United States
PA The Salk Institute For Biological Studies, San Diego, CA, United States (U.S. corporation)
PI US 5449766 19950912
AI US 1994-208531 19940309 (8)

RLI Division of Ser. No. US 1991-733660, filed on 22 Jul 1991, now abandoned
which is a division of Ser. No. US 1989-326984, filed on 22 Mar 1989, now patented, Pat. No. US 5049655
DT Utility
LN.CNT 1307
INCL INCLM: 536/023.500
INCLS: 435/069.100; 435/069.400; 435/240.200; 435/252.300; 435/320.100;
530/300.000; 530/326.000; 536/022.100; 536/023.100
NCL NCLM: 536/023.500
NCLS: 435/069.100; 435/069.400; 435/252.300; 435/320.100; 530/300.000;
530/326.000; 536/022.100; 536/023.100
IC [6]
ICM: C07H012-00
ICS: C07H021-00; C12P021-06; C07K001-00
EXF 435/69.1; 435/69.4; 435/240.2; 435/252.3; 435/320.1; 530/300; 530/326;
536/22.1; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 37 USPATFULL
AN 95:73632 USPATFULL
TI Lipoxin compounds
IN Serhan, Charles N., Boston, MA, United States
PA Brigham & Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5441951 19950815
AI US 1994-260030 19940615 (8)
DT Utility
LN.CNT 2141
INCL INCLM: 514/213.000
INCLS: 514/552.000; 554/219.000; 554/224.000
NCL NCLM: 514/513.000
NCLS: 514/517.000; 514/552.000; 554/219.000; 554/224.000
IC [6]
ICM: C09F007-00
ICS: A01N037-00; A61K031-00
EXF 514/213; 514/552; 554/219; 554/224; 435/28; 424/534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 37 USPATFULL
AN 95:20736 USPATFULL
TI Imidazole 5-position substituted angiotensin II ***antagonists***
IN Duncia, John J. V., Wilmington, DE, United States
Ensinger, Carol L., Newark, DE, United States
Olson, Richard E., Wilmington, DE, United States
Quan, Mimi L., Newark, DE, United States
Santella, III, Joseph B., Springfield, PA, United States
Vanatten, Mary K., Wilmington, DE, United States
PA The Du Pont Merck Pharmaceutical Company, Wilmington, DE, United States
(U.S. corporation)
PI US 5395844 19950307
AI US 1993-72977 19930610 (8)
DT Utility
LN.CNT 5135
INCL INCLM: 514/333.000
INCLS: 546/207.000; 546/210.000; 546/256.000; 546/276.000; 548/253.000;
548/314.700; 548/315.100; 548/335.100; 548/341.500; 548/343.500;
548/346.100; 514/326.000; 514/341.000; 514/381.000; 514/396.000;
514/397.000; 514/399.000; 514/400.000
NCL NCLM: 514/333.000
NCLS: 514/326.000; 514/341.000; 514/381.000; 514/396.000; 514/397.000;
514/399.000; 514/400.000; 544/139.000; 544/333.000; 544/405.000;
546/022.000; 546/023.000; 546/146.000; 546/147.000; 546/174.000;
546/207.000; 546/210.000; 546/256.000; 546/272.400; 546/274.400;
546/274.700; 546/275.100; 548/253.000; 548/314.700; 548/315.100;
548/335.100; 548/341.500; 548/343.500; 548/346.100
IC [6]
ICM: A61K031-415
ICS: C07D401-14; C07D403-02
EXF 548/387; 548/253; 548/319.7; 548/315.1; 548/341.5; 548/335.1; 548/343.5;
548/346.1; 514/396; 514/398; 514/326; 514/341; 514/333; 514/381;
514/397; 514/399; 514/400; 546/207; 546/210; 546/256; 546/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 37 USPATFULL
AN 93:59284 USPATFULL
TI Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
IN Musser, John H., Alameda, CA, United States
Kreft, III, Anthony F., Langhorne, PA, United States
Failli, Amedeo A., Princeton Junction, NJ, United States
Demerson, Christopher A., Kirkland, Canada
Shah, Uresh S., Plainsboro, NJ, United States
Nelson, James A., Washington Crossing, PA, United States
PA American Home Products Corporation, New York, NY, United States (U.S.
corporation)
PI US 5229516 19930720
AI US 1992-911434 19920710 (7)
RLI Continuation-in-part of Ser. No. US 1990-596134, filed on 11 Oct 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-428260, filed on 27 Oct 1989, now abandoned
DT Utility
LN.CNT 2630
INCL INCLM: 546/172.000
INCLS: 546/152.000; 546/174.000; 546/175.000; 546/176.000; 546/180.000
NCL NCLM: 546/172.000
NCLS: 546/152.000; 546/174.000; 546/175.000; 546/176.000; 546/180.000
IC [5]
ICM: C07D215-14
ICS: C07D401-12; C07D405-14
EXF 546/172; 546/152; 546/174; 546/175; 546/176; 546/180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 37 USPATFULL
AN 92:59868 USPATFULL
TI 11.beta.-phenyl-4,9,15-estratrienes, their manufacture and pharmaceutical preparations containing same
IN Ottow, Eckhard, Berlin, Germany, Federal Republic of
Hofmeister, Helmut, Berlin, Germany, Federal Republic of
Scholz, Stefan, Berlin, Germany, Federal Republic of
Neef, Guenter, Berlin, Germany, Federal Republic of
Elger, Walter, Berlin, Germany, Federal Republic of
Beier, Sybille, Berlin, Germany, Federal Republic of
Chwalisz, Krzysztof, Berlin, Germany, Federal Republic of
PA Schering Aktiengesellschaft, Berlin & Bergkamen, Germany, Federal Republic of (non-U.S. corporation)
PI US 5132299 19920721
WO 8900578 19890126
AI US 1990-458668 19900116 (7)
WO 1988-DE447 19880715
19900116 PCT 371 date
19900116 PCT 102(e) date
PRAI DE 1987-3723788 19870716
DT Utility
LN.CNT 537
INCL INCLM: 514/169.000
INCLS: 514/179.000; 552/519.000; 552/623.000; 552/646.000
NCL NCLM: 514/169.000
NCLS: 514/179.000; 552/519.000; 552/623.000; 552/646.000
IC [5]
ICM: C07J001-00
ICS: C07J041-00; A61K031-565

EXF 514/169; 514/179; 552/540; 552/544; 552/548; 552/553; 552/555; 552/595;
552/610; 552/611; 552/623; 552/519; 552/646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 37 USPATFULL
AN 91:75802 USPATFULL
TI Melanin-concentrating hormones
IN Vaughan, Joan, San Diego, CA, United States
Fischer, Wolfgang H., Solano Beach, CA, United States
Rivier, Jean E. F., La Jolla, CA, United States
Nahon, Jean-Louis M., San Diego, CA, United States
Presse, Francoise G., San Diego, CA, United States
Vale, Jr., Wylie W., La Jolla, CA, United States
PA The Salk Institute for Biological Studies, San Diego, CA, United States (U.S. corporation)
PI US 5049655 19910917
AI US 1989-326984 19890322 (7)
DT Utility
LN.CNT 1255
INCL INCLM: 530/326.000
INCLS: 536/027.000; 530/827.000; 530/854.000; 435/069.400; 435/320.100
NCL NCLM: 530/326.000
NCLS: 435/069.400; 435/320.100; 530/827.000; 530/854.000; 536/023.510
IC [5]
ICM: C07K007-64
ICS: C12N015-16
EXF 530/326; 530/827; 530/854; 536/27; 435/69.4; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 37 USPATFULL
AN 90:71762 USPATFULL
TI 2-dithioalkyl-dihydropyridines and pharmaceutical compositions containing them
IN Frigerio, Marco, Milan, Italy
Gandolfi, Carmelo A., Milan, Italy
Tognella, Sergio, Milan, Italy
PA Boehringer Biochemia Robin S.p.A., Milan, Italy (non-U.S. corporation)
PI US 4956369 19900911
AI US 1989-333815 19890406 (7)
RLI Continuation of Ser. No. US 1987-136988, filed on 23 Dec 1987, now abandoned
PRAI IT 1986-22881 19861224
DT Utility
LN.CNT 513
INCL INCLM: 514/274.000
INCLS: 546/321.000; 546/318.000; 546/316.000; 546/157.000; 546/281.000;
546/194.000; 546/256.000; 546/257.000; 546/283.000; 546/284.000; 546/276.000; 546/277.000; 546/278.000; 546/268.000; 546/270.000; 546/271.000; 546/286.000; 546/322.000; 544/360.000; 544/131.000; 544/333.000; 544/324.000; 544/262.000; 544/287.000; 544/318.000
NCL NCLM: 514/274.000
NCLS: 514/248.000; 514/252.160; 514/252.170; 514/252.180; 514/253.010;
514/253.130; 514/256.000; 514/265.000; 514/269.000; 514/275.000; 514/312.000; 514/333.000; 514/334.000; 514/336.000; 514/338.000; 514/339.000; 514/340.000; 514/341.000; 514/342.000; 514/343.000; 514/352.000; 514/356.000; 544/131.000; 544/262.000; 544/287.000; 544/318.000; 544/324.000; 544/333.000; 544/360.000; 546/157.000; 546/194.000; 546/256.000; 546/257.000; 546/268.400; 546/268.700; 546/270.100; 546/270.400; 546/271.400; 546/271.700; 546/272.400; 546/273.400; 546/274.100; 546/280.400; 546/281.400; 546/282.100; 546/283.400; 546/286.000; 546/316.000; 546/318.000; 546/321.000; 546/322.000
IC [5]
ICM: C07D401-12
ICS: A61K031-505
EXF 546/256; 546/257; 546/316; 546/318; 546/286; 546/322; 546/321; 546/270;
546/218; 546/286; 546/157; 546/281; 546/194; 546/283; 546/284; 546/276;
546/277; 546/268; 546/271; 544/318; 544/360; 544/131; 544/333; 544/324;
544/262; 544/287; 514/269; 514/333; 514/334; 514/336; 514/341; 514/344;
514/352; 514/355; 514/356; 514/343; 514/252; 514/255; 514/233; 514/342;
514/256; 514/340; 514/342; 514/275; 514/248; 514/338; 514/339; 514/265;
514/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 37 USPATFULL
AN 83:11260 USPATFULL
TI Antiarrhythmic activity of cetiedil
IN Aurousseau, Michel E. M., Paris, France
PA Innothera, Arcueil, France (non-U.S. corporation)
PI US 4377592 19830322
AI US 1979-88198 19791023 (6)
DT Utility
LN.CNT 542
INCL INCLM: 424/275.000
NCL NCLM: 514/217.030
NCLS: 514/821.000
IC [3]
ICM: A61K031-38
EXF 424/275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 28 kwic

L8 ANSWER 28 OF 37 USPATFULL
AB Mammalian melanin-concentrating hormone (***MCH***) is isolated from
rat tissue, purified and characterized. These ***MCH*** peptides are useful for treating skin disorders, for suppressing the proliferation of skin tumor cells, such as melanomas in mammals,. . . ##STR1## or which are naturally occurring homologs of the peptide with said formula. The peptides which are the naturally occurring ***MCH*** homologs of mammalian species other than rat can also be obtained using the materials disclosed, as demonstrated specifically with human ***MCH*** , which is found to have the same structure as rat ***MCH*** . Also disclosed are the amino acid sequences of, and the nucleotide sequences of the cDNAs which encode, the putative precursors of rat ***MCH*** and human ***MCH*** . These precursors may also include one or more biologically active peptides N-terminally of the mature ***MCH*** 's. Among these peptides, which are thought to be formed from the ***MCH*** precursors, are the peptide with the sequence H-Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2, which is
cross-reactive with antibodies against alpha-MSH and CRF, and the peptide. . .
SUMM . . . from salmon pituitary glands, see Kawauchi, H. et al., Nature, 305, 321-323 (1983), and it was named melanin concentrating hormone (***MCH***). Fish ***MCH*** has been reported to have the opposite effect, i.e., causing dispersal of melanosomes, in amphibians, Wilkes, B. C. et al., B.B.R.C., 122, 613-619 (1984). ***MCH*** is believed to be synthesized in the neurons of the hypothalamus and translocated into the neurohypophysial tissues. ***MCH*** immunoactivity has been reported in hypothalamic extracts of the rat: Baker et al., Gen. Comp. Endocrinol., 50, 423-431 (1983) and Naito, N. et al., Cell Tissue Res., 253, 291-295 (1988). Very crude extracts of an ***MCH*** -like substance from the rat hypothalamus showed a generally parallel response to fish ***MCH*** in a radioimmunoassay (RIA) using an antiserum directed against salmon ***MCH*** , even though the material appeared to have distinct chromatographic properties and showed multiple immunoreactive peaks, not all of which showed. . .

SUMM . . . years, the mammalian hormone remains unisolated and uncharacterized, and as a result, true testing of the biological activity of mammalian ***MCH*** has not heretofore been possible. As a result, great efforts were made to isolate, purify and then characterize and test mammalian ***MCH*** .

SUMM A mammalian ***MCH*** has now been isolated and purified from rat hypothalamus. Characterization of the purified peptide shows that it is 19 amino. . .

SUMM . . . of DNA probes based upon the characterized sequence of the peptide, it was possible to locate cDNAs coding for mammalian ***MCH*** from libraries made using rat and human hypothalamic messenger RNA. By isolating the cDNAs from the positive clones (i.e., those. . . the isolation and sequencing of the mature rat peptide, it was possible to determine that the C-terminus of the native ***MCH*** peptide is in the free acid form.

SUMM The amino acid sequences of the mature ***MCH*** 's of rat and human, as determined by the sequencing of the mature rat peptide and deduced from the sequences of. . . only three positions. The identity of amino acid sequences and close homology in cDNA sequences indicate that all mammalian mature ***MCH*** 's have sequences that are closely similar.

SUMM Further, from the sequencing of the cDNAs encoding the ***MCH*** precursors, it has been found that there is very close homology between the cDNA sequences and the corresponding amino acid. . .

SUMM Inasmuch as it appears that there is very close homology between the mature MCHs, ***MCH*** precursors, and mRNAs enoding these proteins of mammalian species, it is believed that the DNA probes which are based upon the actual rat mature ***MCH*** peptide sequence (or other sequences provided herein using probes based on that rat peptide sequence) will be effective in identifying clones with ***MCH*** -encoding or ***MCH*** precursor-encoding cDNAs in libraries made with mRNAs obtained from appropriate tissue (e.g., hypothalamus) or cell lines of other mammalian species and thus will permit the determination of the sequences, and consequently the synthesis and use, of the mature ***MCH*** of every mammalian species.

SUMM Among the mammalian ***MCH*** 's, the present invention is especially concerned with the mature ***MCH*** having the following structure: ##STR2##

SUMM Reference in the present application to a "mammalian ***MCH*** " is to a mammalian mature ***MCH*** , unless the term is explicitly qualified to refer to a mammalian ***MCH*** precursor.

SUMM Mammalian ***MCH*** is useful to treat humans and other mammals to lighten skin color, as by local or topical application. It is. . . cells, such as melanomas, when suitably applied as by topical application or the like. It is also found that mammalian ***MCH*** can be used to modulate the secretion of ACTH in humans and other mammals and thus can be used to modify the effects of stress, as by systemically administering an effective amount of mammalian ***MCH*** .

SUMM . . . as its sequence
Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2. A mammalian NEI is apparently made in vivo in a mammal by processing beginning with the ***MCH*** precursor of the mammal. The sequences of all mammalian NEI's are closely similar, as indicated by the fact that the. . .

SUMM . . . NGE). Like NEI, a mammalian NGE is apparently also made in vivo in a mammal by processing beginning with the ***MCH*** precursor of the mammal. Further, the sequences of all mammalian NGE's are closely similar, as indicated by the fact that. . .

SUMM The sequence of NEI corresponds to the sequence of amino acids 131-144 of the rat and human ***MCH*** precursors (see Tables 1 and 2, below), taking account of the fact that the glycine at position 144 of the ***MCH*** precursors would provide the NH.sub.2 group of the C-terminal amide of NEI. It has been found that antibodies against human. . .

SUMM The sequences of the NGE's correspond to the sequences of amino acids 110-128 of the ***MCH*** precursors (see Tables 1 and 2, below). Antibodies against human GRF (growth hormone releasing factor) cross-react with NGE, as suggested. . .

SUMM Mammalian melanin-concentrating hormone (***MCH***) has now been isolated from rat hypothalami by acid extraction and purified substantially by immunoaffinity chromatography using antiserum directed against salmon ***MCH*** , gel filtration and two steps of narrow bore high-performance liquid chromatography (HPLC) using octadecyl columns. Several zones of immunoreactivity were. . . indicates that the amino acid structure of all zones are identical. As a result, it is believed that rat hypothalamic ***MCH*** is a cyclic peptide of 19 amino acid residues. More particularly, the invention provides peptides having the following structure: ##STR3## and naturally occurring homologs thereof (i.e., homologous ***MCH*** peptides of mammalian species other than rat and human (for which the structure of the ***MCH*** is identical to that of rat)).

SUMM . . . a synthetic oligonucleotide probe with a sequence which was based on the sequence of residues 1-10 of the above-identified, mature ***MCH*** sequence of rat. Several positive hits were obtained, and the culturing of the positive clones allowed the isolation of cDNAs encoding the entire precursor of rat ***MCH*** . With such cDNA, the nucleotide sequence coding the precursor was determined and, with the nucleotide sequence, the amino acid sequence of the precursor deduced. This work confirmed that the mature ***MCH*** peptide has the above-identified structure and is free acid at the C-terminus. Further, the work provided the information from which. . .

SUMM Substantially the same procedure was followed to isolate and sequence cDNAs encoding the human ***MCH*** precursor. To isolate such cDNAs, a human hypothalamic cDNA library was screened with a probe taken from a portion, encoding part of rat mature ***MCH*** , of the cDNA encoding the rat ***MCH*** precursor. Using the sequence information from the cDNAs encoding the human ***MCH*** precursor, the amino acid sequences of human mature ***MCH*** , its precursor, and human NEI and NGE were deduced.

SUMM A portion, encoding mature ***MCH*** with the dipeptide Arg-Arg, which is a proteolytic processing site, at the N-terminus, of the oligonucleotide sequence of the rat. . .

SUMM Human mature ***MCH*** has the same amino acid sequence as that of rat and, like the rat, is preceded by the dipeptide Arg-Arg in the human ***MCH*** precursor. As indicated in Tables 1 and 2 below, the nucleotide sequence of the cDNA segment encoding human mature ***MCH*** and the Arg-Arg preceding the protein in the precursor differs at only three of 57 positions from the sequence of. . .

SUMM . . . and based on the high degree of homology found in connection with the present invention between rat and human mature ***MCH*** 's and ***MCH*** precursors, and the cDNAs encoding same, possession of the above-identified rat and human nucleotide sequences allows the construction of nucleic acid probes that will hybridize with cDNA fragments, coding for the mature ***MCH*** and ***MCH*** precursor, in a cDNA library of suitable tissue (e.g., the hypothalmus), or a suitable cell line, of any mammalian species,. . . libraries as described above. Thus, possession of the sequences allows deduction of the specific amino acid sequences of the mature ***MCH*** hormone and NEI and NGE of such other species. Such techniques of using a suitable hybridization probe for screening and. . .

SUMM . . . the complementary strand of the above-specified strand of the rat cDNA sequence, was employed for probing for cDNAs encoding human ***MCH*** and its precursor and as expected, hybridized with clones of a human .lambda.gt11 cDNA library prepared with human hypthalamic mRNA.

SUMM Isolation of a cDNA coding for mammalian ***MCH*** or

MCH
precursor of another particular species, as has been accomplished for the rat and human species, will allow, as it has for the rat and human, the determination of the amino acid sequence of the ***MCH*** peptide, as well as of the NEI and NGE, of the species.

SUMM . . . acids in the peptides, using solid-phase or other types of chemical syntheses. Thus, the invention provides methods for producing

<------User Break------>

u

=>

=> d 35 kwic

L8 ANSWER 35 OF 37 USPATFULL

AB Mammalian melanin-concentrating hormone (***MCH***) is isolated from
rat tissue, purified and characterized. These ***MCH*** peptides are useful for treating skin disorders, for suppressing the proliferation of skin tumor cells, such as melanomas in mammals,. . . ##STR1## or which are naturally occurring homologs of the peptide with said formula. The peptides which are the naturally occurring ***MCH*** homologs of mammalian species other than rat can also be obtained using the materials disclosed, as demonstrated specifically with human ***MCH*** , which is found to have the same structure as rat ***MCH*** . Also disclosed are the amino acid sequences of, and the nucleotide sequences of the cDNAs which encode, the putative precursors of rat ***MCH*** and human ***MCH*** . These precursors may also include one or more biologically active peptides N-terminally of the mature ***MCH*** 's. Among these peptides, which are thought to be formed from the ***MCH*** precursors, are the peptide with the sequence H-Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2, which is
cross-reactive with antibodies against alpha-MSH and CRF, and the peptide. . .

SUMM . . . from salmon pituitary glands, see Kawauchi, H. et al., Nature, 305, 321-323 (1983), and it was named melanin concentrating hormone (***MCH***). Fish ***MCH*** has been reported to have the opposite effect, i.e., causing dispersal of melanosomes, in amphibians, Wilkes, B. C. et al., B.B.R.C., 122, 613-619 (1984). ***MCH*** is believed to be synthesized in the neurons of the hypothalamus and translocated into the neurohypophysial tissues. ***MCH*** immunoactivity has been reported in hypothalamic extracts of the rat: Baker et al., Gen. Comp. Endocrinol., 50, 423-431 (1983)) and Naito, N. et al., Cell Tissue Res., 253, 291-295 (1988). Very crude extracts of an ***MCH*** -like substance from the rat hypothalamus showed a generally parallel response to fish ***MCH*** in a radioimmunoassay (RIA) using an antiserum directed against salmon ***MCH*** , even though the material appeared to have distinct chromatographic properties and showed multiple immunoreactive peaks, not all of which showed. . .

SUMM . . . years, the mammalian hormone remains unisolated and uncharacterized, and as a result, true testing of the biological activity of mammalian ***MCH*** has not heretofore been possible. As a result, great efforts were made to isolate, purify and then characterize and test mammalian ***MCH*** .

SUMM A mammalian ***MCH*** has now been isolated and purified from rat
hypothalamus. Characterization of the purified peptide shows that it is 19 amino. . .

SUMM . . . of DNA probes based upon the characterized sequence of the peptide, it was possible to locate cDNAs coding for mammalian ***MCH*** from libraries made using rat and human hypothalamic messenger RNA. By isolating the cDNAs from the positive clones (i.e., those. . . the isolation and sequencing of the mature rat peptide, it was possible to determine that the C-terminus of the native ***MCH*** peptide is in the free acid form.

SUMM The amino acid sequences of the mature ***MCH*** 's of rat and human,
as determined by the sequencing of the mature rat peptide and deduced from the sequences of. . . only three positions. The identity of amino acid sequences and close homology in cDNA sequences indicate that all mammalian mature ***MCH*** 's have sequences that are closely similar.

SUMM Further, from the sequencing of the cDNAs encoding the ***MCH*** precursors, it has been found that there is very close homology between the cDNA sequences and the corresponding amino acid. . .

SUMM Inasmuch as it appears that there is very close homology between the mature MCHs, ***MCH*** precursors, and mRNAs enoding these proteins
of mammalian species, it is believed that the DNA probes which are based upon the actual rat mature ***MCH*** peptide sequence (or other sequences provided herein using probes based on that rat peptide sequence) will be effective in identifying clones with ***MCH*** -encoding or ***MCH*** precursor-encoding cDNAs in libraries made with mRNAs obtained from appropriate tissue (e.g., hypothalamus) or cell lines of other mammalian species and thus will permit the determination of the sequences, and consequently the synthesis and use, of the mature ***MCH*** of every mammalian species.

SUMM Among the mammalian ***MCH*** 's, the present invention is especially
concerned with the mature ***MCH*** having the following structure: ##STR2##

SUMM Reference in the present application to a "mammalian ***MCH*** " is
to a mammalian mature ***MCH*** , unless the term is explicitly qualified to refer to a mammalian ***MCH*** precursor.

SUMM Mammalian ***MCH*** is useful to treat humans and other mammals to
lighten skin color, as by local or topical application. It is. . . cells, such as melanomas, when suitably applied as by topical application or the like. It is also found that mammalian ***MCH*** can be used to modulate the secretion of ACTH in humans and other mammals and thus can be used to modify the effects of stress, as by systemically administering an effective amount of mammalian ***MCH*** .

SUMM . . . as its sequence
Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-
Ile-NH.sub.2. A mammalian NEI is apparently made in vivo in a mammal by
processing beginning with the ***MCH*** precursor of the mammal. The sequences of all mammalian NEI's are closely similar, as indicated by the fact that the. . .

SUMM . . . NGE). Like NEI, a mammalian NGE is apparently also made in vivo
in a mammal by processing beginning with the ***MCH*** precursor of the mammal. Further, the sequences of all mammalian NGE's are closely similar, as indicated by the fact that. . .

SUMM The sequence of NEI corresponds to the sequence of amino acids 131-144
of the rat and human ***MCH*** precursors (see Tables 1 and 2, below), taking account of the fact that the glycine at position 144 of the ***MCH*** precursors would provide the NH.sub.2 group of the C-terminal amide of NEI. It has been found that antibodies against human. . .

SUMM The sequences of the NGE's correspond to the sequences of amino acids 110.128 of the ***MCH*** precursors (see Tables 1 and 2, below). Antibodies against human GRF (growth hormone releasing factor) cross-react with NGE, as suggested. . .

DETD Mammalian melanin-concentrating hormone (***MCH***) has now been
isolated from rat hypothalami by acid extraction and purified substantially by immunoaffinity chromatography using antiserum directed against salmon ***MCH*** , gel filtration and two steps of narrow bore high-performance liquid chromatography (HPLC) using octadecyl columns. Several zones of immunoreactivity were. . . indicates that the amino acid structure of all zones are identical. As a result, it is believed that rat hypothalamic ***MCH*** is a cyclic peptide of 19 amino acid residues. More particularly, the invention provides peptides having the following structure: ##STR3## and naturally occurring homologs thereof (i.e., homologous ***MCH*** peptides of mammalian species other than rat and human (for which the structure of the

MCH is identical to that of rat)).
DETD . . . a synthetic oligonucleotide probe with a sequence which was based on the sequence of residues 1-10 of the above-identified, mature ***MCH*** sequence of rat. Several positive hits were obtained, and the culturing of the positive clones allowed the isolation of cDNAs encoding the entire precursor of rat ***MCH*** . With such cDNA, the nucleotide sequence coding the precursor was determined and, with the nucleotide sequence, the amino acid sequence of the precursor deduced. This work confirmed that the mature ***MCH*** peptide has the above-identified structure and is free acid at the C-terminus. Further, the work provided the information from which. . .
DETD Substantially the same procedure was followed to isolate and sequence cDNAs encoding the human ***MCH*** precursor. To isolate such cDNAs,
a human hypothalamic cDNA library was screened with a probe taken from a
portion, encoding part of rat mature ***MCH*** , of the cDNA encoding the rat ***MCH*** precursor. Using the sequence information from the cDNAs encoding the human ***MCH*** precursor, the amino acid sequences of human mature ***MCH*** , its precursor, and human NEI and NGE were deduced.
DETD A portion, encoding mature ***MCH*** with the dipeptide Arg-Arg, which is a proteolytic processing site, at the N-terminus, of the oligonucleotide sequence of the rat. . .
DETD Human mature ***MCH*** has the same amino acid sequence as that of
rat and, like the rat, is preceded by the dipeptide Arg-Arg in the human ***MCH*** precursor. As indicated in Tables 1 and 2 below, the nucleotide sequence of the cDNA segment encoding human mature ***MCH*** and the Arg-Arg preceding the protein in the precursor
<------User Break------>
u
=>
=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		78.59	78.74

STN INTERNATIONAL LOGOFF AT 12:25:19 ON 13 SEP 2000

FILE 'HOME' ENTERED AT 12:26:30 ON 13 SEP 2000

=> file medline, embase, biosis

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.15	0.15

FILE 'MEDLINE' ENTERED AT 12:26:41 ON 13 SEP 2000

FILE 'EMBASE' ENTERED AT 12:26:41 ON 13 SEP 2000

FILE 'BIOSIS' ENTERED AT 12:26:41 ON 13 SEP 2000

=> s melanocyte concentrating hormone or mch

L1 4209 MELANOCYTE CONCENTRATING HORMONE OR MCH

=> s l1 and antagoni?

L2 234 L1 AND ANTAGONI?

=> s l2 and (eat? or appetite or weight)

L3 16 L2 AND (EAT? OR APPETITE OR WEIGHT)

=> duplicate remove l3

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L3
L4 9 DUPLICATE REMOVE L3 (7 DUPLICATES REMOVED)

=> d 1-9

L4 ANSWER 1 OF 9 MEDLINE DUPLICATE 1
AN 2000119108 MEDLINE
DN 20119108
TI Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system.
AU Hanada R; Nakazato M; Matsukura S; Murakami N; Yoshimatsu H; Sakata T
CS Department of Internal Medicine I, School of Medicine, Oita Medical University, Oita, 879-5593, Japan.
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2000 Feb 5) 268 (1) 88-91.
Journal code: 9Y8. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 200005
EW 20000501

L4 ANSWER 2 OF 9 MEDLINE DUPLICATE 2
AN 1999347735 MEDLINE
DN 99347735
TI Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1.
AU Chambers J; Ames R S; Bergsma D; Muir A; Fitzgerald L R; Hervieu G; Dytko G M; Foley J J; Martin J; Liu W S; Park J; Ellis C; Ganguly S; Konchar S; Cluderay J; Leslie R; Wilson S; Sarau H M
CS Department of Molecular Screening Technologies, New Frontiers Science Park, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.. Jon_Chambers-1@sbphrd.com

SO NATURE, (1999 Jul 15) 400 (6741) 261-5.
Journal code: NSC. ISSN: 0028-0836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199910

L4 ANSWER 3 OF 9 MEDLINE
AN 1999008618 MEDLINE
DN 99008618
TI Leptin decreases food intake induced by melanin-concentrating hormone (***MCH***), galanin (GAL) and neuropeptide Y (NPY) in the rat.
AU Sahu A
CS Department of Cell Biology and Physiology, University of Pittsburgh School
of Medicine, PA 15261, USA.. asahu@vms.cis.pitt.edu
SO ENDOCRINOLOGY, (1998 Nov) 139 (11) 4739-42.
Journal code: EGZ. ISSN: 0013-7227.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199901

L4 ANSWER 4 OF 9 MEDLINE DUPLICATE 3
AN 1998236737 MEDLINE
DN 98236737
TI Melanin-concentrating hormone: a functional melanocortin ***antagonist*** in the hypothalamus.
AU Ludwig D S; Mountjoy K G; Tatro J B; Gillette J A; Frederich R C; Flier J S; Maratos-Flier E
CS Department of Medicine, Beth Israel-Deaconess Medical Center, Boston, Masachussetts, USA.
NC R08-DK-02440 (NIDDK)
MH-44694 (NIMH)
SO AMERICAN JOURNAL OF PHYSIOLOGY, (1998 Apr) 274 (4 Pt 1) E627-33.
Journal code: 3U8. ISSN: 0002-9513.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199808
EW 19980801

L4 ANSWER 5 OF 9 MEDLINE
AN 96270476 MEDLINE
DN 96270476
TI Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice.
AU Mantzoros C S; Qu D; Frederich R C; Susulic V S; Lowell B B; Maratos-Flier
E; Flier J S
CS Division of Endocrinology, Beth Israel Hospital, Boston, Massachusetts, USA.
NC P30DK462000 (NIDDK)
K08 HL-02564 (NHLBI)
K08 DK-02119 (NIDDK)
SO DIABETES, (1996 Jul) 45 (7) 909-14.
Journal code: E8X. ISSN: 0012-1797.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199610

L4 ANSWER 6 OF 9 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.DUPLICATE 4
AN 95322343 EMBASE
DN 1995322343
TI Toxicological studies of lafutidine (FRG-8813) 5. Thirteen-week repeated dose toxicity study by oral administration to beagle dogs with a recovery period of 4 weeks.
AU Kobayashi K.; Hashiguchi J.-I.; Okamura T.; Enomoto M.; Hayashi Y.
CS BRCFDP, 582-2 Arahama, Shioshinden,Iwata-gun, Shizuoka 437 12, Japan
SO Pharmacometrics, (1995) 50/4 (421-438).
ISSN: 0300-8533 CODEN: OYYAA2
CY Japan
DT Journal; Article
FS 030 Pharmacology
037 Drug Literature Index
052 Toxicology
LA Japanese
SL English

L4 ANSWER 7 OF 9 MEDLINE
AN 93182873 MEDLINE
DN 93182873
TI Distribution of secretory leukoprotease inhibitor in the human nasal airway.
AU Lee C H; Igarashi Y; Hohman R J; Kaulbach H; White M V; Kaliner M A
CS Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
SO AMERICAN REVIEW OF RESPIRATORY DISEASE, (1993 Mar) 147 (3) 710-6.
Journal code: 426. ISSN: 0003-0805.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199306

L4 ANSWER 8 OF 9 MEDLINE
AN 93265734 MEDLINE
DN 93265734
TI Inhibition of delta aminolevulinic acid dehydratase activity by aluminum.
AU Zaman K; Zaman W; Dabrowski Z; Miszta H
CS Department of Pathology, School of Medicine, University of Pennsylvania, Philadelphia.
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. C: COMPARATIVE PHARMACOLOGY AND
TOXICOLOGY, (1993 Feb) 104 (2) 269-73.
Journal code: DNX. ISSN: 0742-8413.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199308

L4 ANSWER 9 OF 9 MEDLINE DUPLICATE 5
AN 93115167 MEDLINE
DN 93115167
TI M1 and M3 muscarinic ***antagonists*** inhibit human nasal glandular secretion in vitro.
AU Mullol J; Baraniuk J N; Logun C; Merida M; Hausfeld J; Shelhamer J H; Kaliner M A
CS Servei de Pneumologia i All`ergia Respirat`oria, Hospital Clinic, Barcelona, Spain..
SO JOURNAL OF APPLIED PHYSIOLOGY, (1992 Nov) 73 (5) 2069-73.
Journal code: HEG. ISSN: 8750-7587.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199304

=> d 1-4 abs

L4 ANSWER 1 OF 9 MEDLINE DUPLICATE 1

AB Agouti protein and agouti-related protein (AGRP) ***antagonize*** alpha-melanocyte-stimulating hormone that binds to and activates the melanocortin-4 receptor (MC4-R) in the hypothalamus, thereby stimulating food intake. Melanin-concentrating hormone (***MCH***) and orexin are orexigenic peptides that specifically are synthesized in the lateral hypothalamus. ***MCH*** gene expression was augmented in A(y)/a (agouti) mice which overexpress agouti protein, but orexin mRNA was not. AGRP administered intracerebroventricularly into wild-type rats augmented ***MCH*** but not orexin gene expression. Also, SHU9119, a peptidergic ***antagonist*** of MC4-R, increased only ***MCH*** mRNA. These findings indicate that interruption of signaling at MC4-R activates the ***MCH*** but not the orexin gene. The biosyntheses of ***MCH*** and orexin are regulated through different pathways. Copyright 2000 Academic Press.

L4 ANSWER 2 OF 9 MEDLINE DUPLICATE 2

AB The underlying causes of obesity are poorly understood but probably involve complex interactions between many neurotransmitter and neuropeptide systems involved in the regulation of food intake and energy balance. Three pieces of evidence indicate that the neuropeptide melanin-concentrating hormone (***MCH***) is an important component of this system. First, ***MCH*** stimulates feeding when injected directly into rat brains; second, the messenger RNA for the ***MCH*** precursor is upregulated in the hypothalamus of genetically obese mice and in fasted animals; and third, mice lacking ***MCH*** ***eat*** less and are lean. ***MCH*** ***antagonists*** might, therefore, provide a treatment for obesity. However, the development of such molecules has been hampered because the identity of the ***MCH*** receptor has been unknown until now. Here we show that the 353-amino-acid human orphan G-protein-coupled receptor SLC-1 expressed in HEK293 cells binds ***MCH*** with sub-nanomolar affinity, and is stimulated by ***MCH*** to mobilize intracellular Ca2+ and reduce forskolin-elevated cyclic AMP levels. We also show that SLC-1 messenger RNA and protein is expressed in the ventromedial and dorsomedial nuclei of the hypothalamus, consistent with a role for SLC-1 in mediating the effects of ***MCH*** on feeding.

L4 ANSWER 3 OF 9 MEDLINE

AB Recent evidence suggests that leptin reduces food intake (FI) by acting at the hypothalamic level. Leptin decreases hypothalamic neuropeptide Y (NPY), melanin-concentrating hormone (***MCH***) and galanin (GAL) gene expression in rats. The purpose of the present study was to test the hypothesis that leptin decreases FI by additionally modulating the action of NPY, ***MCH*** or GAL in the hypothalamus. Intracerebroventricular (i.c.v.) administration of NPY, ***MCH*** or GAL induced FI in satiated rats. A prior i.c.v. injection of leptin (4 microg) completely prevented the increase of FI either by ***MCH*** , GAL or NPY. These results suggest that modulation of post-synaptic actions of ***MCH*** , GAL and NPY is one of the mechanisms of leptin signaling in the hypothalamus.

L4 ANSWER 4 OF 9 MEDLINE DUPLICATE 3

AB Melanin-concentrating hormone (***MCH***) and alpha-melanocyte-stimulating hormone (alpha-MSH) demonstrate opposite actions on skin coloration in teleost fish. Both peptides are present in the mammalian brain, although their specific physiological roles remain largely unknown. In this study, we examined the interactions between ***MCH*** and alpha-MSH after intracerebroventricular administration in rats. ***MCH*** increased food intake in a dose-dependent manner and lowered plasma glucocorticoid levels through a mechanism involving ACTH. In contrast, alpha-MSH decreased food intake and increased glucocorticoid levels. ***MCH*** , at a twofold molar excess, ***antagonized*** both actions of alpha-MSH. alpha-MSH, at a threefold molar excess, blocked the orexigenic properties of ***MCH*** . ***MCH*** did not block alpha-MSH binding or the ability of alpha-MSH to induce cAMP in cells expressing either the MC3 or MC4 receptor, the principal brain alpha-MSH receptor subtypes. These data suggest that ***MCH*** and alpha-MSH exert opposing and ***antagonistic*** influences on feeding behavior and the stress response and may function in a coordinate manner to regulate metabolism through a novel mechanism mediated in part by an ***MCH*** receptor.

=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		8.42	8.57

STN INTERNATIONAL LOGOFF AT 12:31:46 ON 13 SEP 2000

FILE 'HOME' ENTERED AT 10:08:19 ON 14 SEP 2000

=> file medline

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.15 0.15

FILE 'MEDLINE' ENTERED AT 10:08:46 ON 14 SEP 2000

FILE LAST UPDATED: 7 SEP 2000 (20000907/UP). FILE COVERS 1960 TO DATE.

MEDLINE has been reloaded to reflect the annual MeSH changes made by the National Library of Medicine for 2000. Enter HELP RLOAD for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
SUBSTANCE IDENTIFICATION.

=> s caffeine

L1 15528 CAFFEINE

=> s l1 and weight loss

445116 WEIGHT
222176 LOSS
18662 WEIGHT LOSS
(WEIGHT(W)LOSS)
L2 54 L1 AND WEIGHT LOSS

=> s l2 and review

237562 REVIEW
L3 2 L2 AND REVIEW

=> d 1-2

L3 ANSWER 1 OF 2 MEDLINE
AN 2000186121 MEDLINE
DN 20186121
TI The effectiveness of popular, non-prescription ***weight*** ***loss*** supplements [see comments].
CM Comment in: Med J Aust 1999 Dec 6-20;171(11-12):599-600
AU Egger G; Cameron-Smith D; Stanton R
CS School of Health Sciences, Deakin University, Melbourne, Vic.. eggergj@ozemail.com.au
SO MEDICAL JOURNAL OF AUSTRALIA, (1999 Dec 6-20) 171 (11-12) 604-8. Ref: 69
Journal code: M26. ISSN: 0025-729X.
CY Australia
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals; Cancer Journals
EM 200006
EW 20000602

L3 ANSWER 2 OF 2 MEDLINE
AN 97081303 MEDLINE
DN 97081303
TI Dexfenfluramine. An updated ***review*** of its therapeutic use in the management of obesity.
AU Davis R; Faulds D
CS Adis International Limited, Auckland, New Zealand.
SO DRUGS, (1996 Nov) 52 (5) 696-724. Ref: 167
Journal code: EC2. ISSN: 0012-6667.
CY New Zealand
DT (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 199706

=> s water and weight and obesity

212635 WATER
445116 WEIGHT
51496 OBESITY
L4 597 WATER AND WEIGHT AND OBESITY

=> s water and obesity and eat?

212635 WATER
51496 OBESITY
41129 EAT?
L5 114 WATER AND OBESITY AND EAT?

=> d 100-114

L5 ANSWER 100 OF 114 MEDLINE
AN 77220067 MEDLINE
DN 77220067
TI [Dietary behavior and cardiovascular diseases]. Comportement alimentaire et maladies cardiovasculaires.
AU Debry G
SO ANNALES DE LA NUTRITION ET DE L ALIMENTATION, (1976) 30 (2-3) 219-33.
Ref: 102
Journal code: 5N0. ISSN: 0003-4037.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 197710

L5 ANSWER 101 OF 114 MEDLINE
AN 77099409 MEDLINE
DN 77099409
TI The role of vasopressin and prolactin in abnormal salt and ***water*** metabolism of obese patients before and after fasting and during refeeding.
AU Drenick E J; Carlson H E; Robertson G L; Hershman J M
SO METABOLISM: CLINICAL AND EXPERIMENTAL, (1977 Mar) 26 (3) 309-17.
Journal code: MUM. ISSN: 0026-0495.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197705

L5 ANSWER 102 OF 114 MEDLINE
AN 77011151 MEDLINE
DN 77011151
TI Metabolic responses to dietary supplements of bran.

AU Southgate D A; Branch W J; Hill M J; Drasar B S; Walters R L; Davies P S;
Baird I M
SO METABOLISM: CLINICAL AND EXPERIMENTAL, (1976 Oct) 25 (10) 1129-35.
Journal code: MUM. ISSN: 0026-0495.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197701

L5 ANSWER 103 OF 114 MEDLINE
AN 74109640 MEDLINE
DN 74109640
TI Role of past experience on food-motivated behavior of obese humans.
AU Singh D; Sikes S
SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1974 Mar) 86 (3) 503-8.
Journal code: HVR. ISSN: 0021-9940.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197406

L5 ANSWER 104 OF 114 MEDLINE
AN 74077040 MEDLINE
DN 74077040
TI Food motivation and body weight levels in hypothalamic hyperphage rats: a dual lipostat model of hunger and appetite.
AU Sclafani A; Kluge L
SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1974 Jan) 86 (1) 28-46.
Journal code: HVR. ISSN: 0021-9940.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197404

L5 ANSWER 105 OF 114 MEDLINE
AN 74009073 MEDLINE
DN 74009073
TI Feeding and drinking pathways between medial and lateral hypothalamus in the rat.
AU Sclafani A; Berner C N; Maul G
SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1973 Oct) 85 (1) 29-51.
Journal code: HVR. ISSN: 0021-9940.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197401

L5 ANSWER 106 OF 114 MEDLINE
AN 73234043 MEDLINE
DN 73234043
TI Basic drives.
AU Wayner M J; Carey R J
SO ANNUAL REVIEW OF PSYCHOLOGY, (1973) 24 53-80. Ref: 156
Journal code: 6EB. ISSN: 0066-4308.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 197311

L5 ANSWER 107 OF 114 MEDLINE
AN 72242491 MEDLINE
DN 72242491
TI Taste sensitivity and susceptibility to external influence in obese and normal weight subjects.
AU Grinker J; Hirsch J; Smith D V
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, (1972 Jun) 22 (3) 320-5.
Journal code: JN3. ISSN: 0022-3514.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197211

L5 ANSWER 108 OF 114 MEDLINE
AN 71018840 MEDLINE
DN 71018840
TI [Importance of ***water*** quantity in infant nutrition, especially in the fight against ***obesity***].
L'importance de la ration hydrique dans l'alimentation du nourrisson, en particulier dans la lutte contre l'obesite.
AU Du Pan M
SO PEDIATRIE, (1968 Apr-May) 23 (3) 295-309.
Journal code: OY8. ISSN: 0031-4021.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
EM 197101

L5 ANSWER 109 OF 114 MEDLINE
AN 70284941 MEDLINE
DN 70284941
TI Metabolic aspects of ***obesity*** .
AU Gordon E S
SO ADVANCES IN METABOLIC DISORDERS, (1970) 4 229-96. Ref: 195
Journal code: 2NR. ISSN: 0065-2903.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 197012

L5 ANSWER 110 OF 114 MEDLINE
AN 70162073 MEDLINE
DN 70162073
TI Metabolic adaptations in meal-fed rats: effects of increased meal frequency or ad libitum feeding in rats previously adapted to a single daily meal.
AU Muiruri K L; Leveille G A
SO JOURNAL OF NUTRITION, (1970 Apr) 100 (4) 450-60.
Journal code: JEV. ISSN: 0022-3166.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197007

L5 ANSWER 111 OF 114 MEDLINE
AN 70133081 MEDLINE
DN 70133081
TI Oral anticonception. Side effects and risks.
AU Ostergaard E
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, (1969) 48 Suppl 1:57-72.
Journal code: 1E8. ISSN: 0001-6349.
CY Sweden
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM 197006

L5 ANSWER 112 OF 114 MEDLINE
AN 70087770 MEDLINE
DN 70087770
TI Hunger and satiety.
AU Morgane P J; Jacobs H L
SO WORLD REVIEW OF NUTRITION AND DIETETICS, (1969) 10 100-213. Ref: 249
Journal code: XQN. ISSN: 0084-2230.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
EM 197004

L5 ANSWER 113 OF 114 MEDLINE
AN 70003949 MEDLINE
DN 70003949
TI Effects of weight changes produced by exercise, food restriction, or overeating on body composition.
AU Oscai L B; Holloszy J O
SO JOURNAL OF CLINICAL INVESTIGATION, (1969 Nov) 48 (11) 2124-8.
Journal code: HS7. ISSN: 0021-9738.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 197001

L5 ANSWER 114 OF 114 MEDLINE
AN 67164838 MEDLINE
DN 67164838
TI Defective thirst mechanism secondary to a hypothalamic lesion: studies in a child with adipsia, polyphagia, ***obesity*** , and persistent hyperosmolality.
AU Travis L B; Dodge W F; Waggener J D; Kashemsant C
SO JOURNAL OF PEDIATRICS, (1967 Jun) 70 (6) 915-26.
Journal code: JLZ. ISSN: 0022-3476.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 196709

=> d his

(FILE 'HOME' ENTERED AT 10:08:19 ON 14 SEP 2000)

FILE 'MEDLINE' ENTERED AT 10:08:46 ON 14 SEP 2000
L1 15528 S CAFFEINE
L2 54 S L1 AND WEIGHT LOSS
L3 2 S L2 AND REVIEW
L4 597 S WATER AND WEIGHT AND OBESITY
L5 114 S WATER AND OBESITY AND EAT?

=> s l5 and review

237562 REVIEW
L6 4 L5 AND REVIEW

=> d 1-4

L6 ANSWER 1 OF 4 MEDLINE
AN 2000025951 MEDLINE
DN 20025951
TI Intense sweeteners and energy density of foods: implications for weight control.
AU Drewnowski A
CS Departments of Epidemiology and Medicine, and Nutritional Sciences Program, University of Washington, Seattle, WA 98195-3410, USA.
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION, (1999 Oct) 53 (10) 757-63. Ref: 62
Journal code: EJC. ISSN: 0954-3007.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200002
EW 20000204

L6 ANSWER 2 OF 4 MEDLINE
AN 97300473 MEDLINE
DN 97300473
TI Meal frequency and energy balance.
AU Bellisle F; McDevitt R; Prentice A M
CS INSERM U341, Hotel Dieu de Paris, France.
SO BRITISH JOURNAL OF NUTRITION, (1997 Apr) 77 Suppl 1 S57-70. Ref: 48
Journal code: AZ4. ISSN: 0007-1145.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199708
EW 19970801

L6 ANSWER 3 OF 4 MEDLINE
AN 85123535 MEDLINE
DN 85123535
TI A 13-year ***review*** of jejunoileal bypass.
AU McFarland R J; Gazet J C; Pilkington T R
SO BRITISH JOURNAL OF SURGERY, (1985 Feb) 72 (2) 81-7.
Journal code: B34. ISSN: 0007-1323.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 198506

L6 ANSWER 4 OF 4 MEDLINE
AN 83120251 MEDLINE
DN 83120251
TI Bulimia: the binge ***eating*** syndrome.
AU Humphries L L; Wrobel S
SO SOUTHERN MEDICAL JOURNAL, (1983 Feb) 76 (2) 181-4. Ref: 18
Journal code: UVH. ISSN: 0038-4348.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198305

=> s obesity and review and eat?

51496 OBESITY
237562 REVIEW
41129 EAT?

L7 108 OBESITY AND REVIEW AND EAT?

=> s l7 and therap?

1971017 THERAP?
L8 50 L7 AND THERAP?

=> d 30-50

L8 ANSWER 30 OF 50 MEDLINE
AN 94225965 MEDLINE
DN 94225965
TI [Psychopharmacologic treatment of bulimia nervosa].
Tratamiento psicofarmacologico de la bulimia nerviosa.
AU Chinchilla Moreno A; Padin Calo J J; Llinares Zaragoza C; Vega Pinero M;
Arias Horcajadas F
CS Servicio de Psiquitria, Hospital Ramon y Cajal, Madrid.
SO ACTAS LUSO-ESPANOLAS DE NEUROLOGIA, PSIQUIATRIA Y CIENCIAS AFINES, (1993
Nov-Dec) 21 (6) 211-20. Ref: 85
Journal code: 2AM. ISSN: 0300-5062.
CY Spain
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Spanish
EM 199408

L8 ANSWER 31 OF 50 MEDLINE
AN 93348352 MEDLINE
DN 93348352
TI The effects of dieting on ***eating*** behavior: a three-factor model.
AU Lowe M R
CS Division of Clinical Psychology, Hahnemann University, Philadelphia, Pennsylvania 19102-1192..
NC 1 R15 DK 38864-01 (NIDDK)
SO PSYCHOLOGICAL BULLETIN, (1993 Jul) 114 (1) 100-21. Ref: 150
Journal code: QE8. ISSN: 0033-2909.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
EM 199311

L8 ANSWER 32 OF 50 MEDLINE
AN 93139273 MEDLINE
DN 93139273
TI Opiate antagonists and ***eating*** behavior in humans: a ***review*** .
AU de Zwaan M; Mitchell J E
CS Department of Psychiatry, University of Vienna, Austria.
SO JOURNAL OF CLINICAL PHARMACOLOGY, (1992 Dec) 32 (12) 1060-72. Ref: 60
Journal code: HT9. ISSN: 0091-2700.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199304

L8 ANSWER 33 OF 50 MEDLINE
AN 92347204 MEDLINE
DN 92347204
TI Dexfenfluramine. A ***review*** of its pharmacological properties and ***therapeutic*** potential in ***obesity*** [published erratum appears in Drugs 1992 Jul;44(1):8].
AU McTavish D; Heel R C
CS Adis International Limited, Auckland, New Zealand..
SO DRUGS, (1992 May) 43 (5) 713-33. Ref: 81
Journal code: EC2. ISSN: 0012-6667.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199211

L8 ANSWER 34 OF 50 MEDLINE
AN 92312530 MEDLINE
DN 92312530
TI Combination of very-low-calorie diet and behavior modification in the treatment of ***obesity*** .
AU Atkinson R L; Fuchs A; Pastors J G; Saunders J T
CS Department of Internal Medicine, Eastern Virginia Medical School, Veterans
Affairs Medical Center, Hampton 23667.
SO AMERICAN JOURNAL OF CLINICAL NUTRITION, (1992 Jul) 56 (1 Suppl) 199S-202S.
Journal code: 3EY. ISSN: 0002-9165.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199210

L8 ANSWER 35 OF 50 MEDLINE
AN 92255839 MEDLINE
DN 92255839
TI The problem of ***obesity*** : fundamental concepts of energy metabolism gone awry.
AU Dausch J G
CS National Center for Health Statistics, Centers for Disease Control, Hyattsville, Maryland 20782..
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, (1992) 31 (4) 271-98.
Ref: 70
Journal code: AF0. ISSN: 1040-8398.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199208

L8 ANSWER 36 OF 50 MEDLINE
AN 91264661 MEDLINE
DN 91264661
TI The obese patient.
AU Kaczmarczyk W
CS WA Faculty of the Family Medicine Programme..
SO AUSTRALIAN FAMILY PHYSICIAN, (1991 Apr) 20 (4) 417, 421.
Journal code: 9EC. ISSN: 0300-8495.
CY Australia
DT Journal; Article; (JOURNAL ARTICLE)
LA English
EM 199109

L8 ANSWER 37 OF 50 MEDLINE
AN 91123619 MEDLINE
DN 91123619
TI Nutrition management for individuals with noninsulin-dependent diabetes mellitus in the 1990s: a ***review*** by the Diabetes Care and Education dietetic practice group.
AU Beebe C A; Pastors J G; Powers M A; Wylie-Rosett J
CS St. James Hospital and Health Centers, Chicago Heights, IL 60420..

SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1991 Feb) 91 (2) 196-202,
205-7. Ref: 31
Journal code: H6F. ISSN: 0002-8223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199105

L8 ANSWER 38 OF 50 MEDLINE
AN 87269200 MEDLINE
DN 87269200
TI The effect of gut peptides on hunger, satiety, and food intake in humans.
AU Smith G P; Gibbs J
NC MH-00149 (NIMH)
MH-40010 (NIMH)
MH-15455 (NIMH)
+
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1987) 499 132-6. Ref: 20
Journal code: 5NM. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals; Cancer Journals
EM 198710

L8 ANSWER 39 OF 50 MEDLINE
AN 86206581 MEDLINE
DN 86206581
TI Effects of cholecystokinin and caerulein on human ***eating*** behavior and pain sensation: a ***review*** .
AU Stacher G
SO PSYCHONEUROENDOCRINOLOGY, (1986) 11 (1) 39-48. Ref: 52
Journal code: QGC. ISSN: 0306-4530.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 198608

L8 ANSWER 40 OF 50 MEDLINE
AN 86086410 MEDLINE
DN 86086410
TI Behavior ***therapy*** techniques applied to ***eating*** , exercise, and diet modification in childhood ***obesity*** .
AU Varni J W; Banis H T
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, (1985 Dec) 6 (6)
367-72.
Journal code: HTF. ISSN: 0196-206X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198604

L8 ANSWER 41 OF 50 MEDLINE
AN 85206548 MEDLINE
DN 85206548
TI The ***therapeutic*** potential of cholecystokinin.
AU Smith G P
NC MH-00149 (NIMH)
MH-15455 (NIMH)
SO INTERNATIONAL JOURNAL OF OBESITY, (1984) 8 Suppl 1 35-8. Ref: 19
Journal code: GR9. ISSN: 0307-0565.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 198509

L8 ANSWER 42 OF 50 MEDLINE
AN 85183614 MEDLINE
DN 85183614
TI ***Obesity*** a family matter: creating new behavior.
AU Frankle R T
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1985 May) 85 (5) 597-602.
Ref: 63
Journal code: H6F. ISSN: 0002-8223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198508

L8 ANSWER 43 OF 50 MEDLINE
AN 85123535 MEDLINE
DN 85123535
TI A 13-year ***review*** of jejunoileal bypass.
AU McFarland R J; Gazet J C; Pilkington T R
SO BRITISH JOURNAL OF SURGERY, (1985 Feb) 72 (2) 81-7.
Journal code: B34. ISSN: 0007-1323.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 198506

L8 ANSWER 44 OF 50 MEDLINE
AN 84120614 MEDLINE
DN 84120614
TI The current status of treatment for ***obesity*** in adults.
AU Stunkard A J
NC MH31050 (NIMH)
SO RESEARCH PUBLICATIONS - ASSOCIATION FOR RESEARCH IN NERVOUS AND MENTAL
DISEASE, (1984) 62 157-73.
Journal code: R6P. ISSN: 0091-7443.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198405

L8 ANSWER 45 OF 50 MEDLINE
AN 83120251 MEDLINE
DN 83120251
TI Bulimia: the binge ***eating*** syndrome.
AU Humphries L L; Wrobel S
SO SOUTHERN MEDICAL JOURNAL, (1983 Feb) 76 (2) 181-4. Ref: 18
Journal code: UVH. ISSN: 0038-4348.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198305

L8 ANSWER 46 OF 50 MEDLINE
AN 82100958 MEDLINE
DN 82100958
TI Limitations of behavioral treatment of ***obesity*** : ***review***

and analysis.
AU Foreyt J P; Goodrick G K; Gotto A M
SO JOURNAL OF BEHAVIORAL MEDICINE, (1981 Jun) 4 (2) 159-74.
Journal code: J58. ISSN: 0160-7715.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198205

L8 ANSWER 47 OF 50 MEDLINE
AN 81007593 MEDLINE
DN 81007593
TI Feeding children with Down's syndrome.
AU Pipes P L; Holm V A
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1980 Sep) 77 (3) 277-82.
Journal code: H6F. ISSN: 0002-8223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198101

L8 ANSWER 48 OF 50 MEDLINE
AN 79047387 MEDLINE
DN 79047387
TI Surgical treatment of ***obesity*** : a ***review*** of our experience and an analysis of published reports.
AU Bray G A; Greenway F L; Barry R E; Benfield J R; Fiser R L; Dahms W T;
Atkinson R L; Schwartz A A
SO INTERNATIONAL JOURNAL OF OBESITY, (1977) 1 (4) 331-67. Ref: 182
Journal code: GR9. ISSN: 0307-0565.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 197903

L8 ANSWER 49 OF 50 MEDLINE
AN 79047384 MEDLINE
DN 79047384
TI ***Eating*** in public places: a ***review*** of reports of the direct observation of ***eating*** behavior.
AU Stunkard A; Kaplan D
SO INTERNATIONAL JOURNAL OF OBESITY, (1977) 1 (1) 89-101.
Journal code: GR9. ISSN: 0307-0565.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197903

L8 ANSWER 50 OF 50 MEDLINE
AN 74097632 MEDLINE
DN 74097632
TI A ***review*** of behavioral approaches to weight control.
AU Abramson E E
SO BEHAVIOUR RESEARCH AND THERAPY, (1973 Nov) 11 (4) 547-56. Ref: 57
Journal code: 9KP. ISSN: 0005-7967.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
EM 197405

=> d 20-29

L8 ANSWER 20 OF 50 MEDLINE
AN 1998046735 MEDLINE
DN 98046735
TI Psychological effects of weight cycling in obese persons: a ***review*** and research agenda.
AU Foster G D; Sarwer D B; Wadden T A
CS University of Pennsylvania School of Medicine, Philadelphia 19104-2648, USA.
NC RO1 DK50058-02 (NIDDK)
K02 MH00702-07 (NIMH)
P30-MH45178-07 (NIMH)
SO OBESITY RESEARCH, (1997 Sep) 5 (5) 474-88. Ref: 99
Journal code: CDE. ISSN: 1071-7323.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199802
EW 19980204

L8 ANSWER 21 OF 50 MEDLINE
AN 1998036789 MEDLINE
DN 98036789
TI Binge ***eating*** disorder: clinical features and treatment of a new diagnosis.
AU de Zwaan M; Mitchell J E; Raymond N C; Spitzer R L
CS Department of Psychiatry, University of Vienna, Austria.
SO HARVARD REVIEW OF PSYCHIATRY, (1994 Mar-Apr) 1 (6) 310-25. Ref: 77
Journal code: COW. ISSN: 1067-3229.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199802
EW 19980204

L8 ANSWER 22 OF 50 MEDLINE
AN 97276285 MEDLINE
DN 97276285
TI Sibutramine: a ***review*** of the pharmacology of a novel anti-***obesity*** agent.
AU Stock M J
CS Department of Physiology, St. George's Hospital Medical School, University
of London, UK.
SO INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS, (1997
Mar) 21 Suppl 1 S25-9. Ref: 29
Journal code: BTX. ISSN: 0307-0565.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199708
EW 19970803

L8 ANSWER 23 OF 50 MEDLINE
AN 97149824 MEDLINE
DN 97149824
TI Adaptation of African-American cultural and food preferences in end-stage renal disease diets.

AU Patel C; Nicol A
CS Total Renal Care, San Leandro, CA, USA.
SO ADVANCES IN RENAL REPLACEMENT THERAPY, (1997 Jan) 4 (1) 30-9. Ref: 14
Journal code: CE2. ISSN: 1073-4449.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199706

L8 ANSWER 24 OF 50 MEDLINE
AN 96248134 MEDLINE
DN 96248134
TI Psychological consequences of food restriction.
AU Polivy J
CS University of Toronto, Mississauga, Ontario, Canada.
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1996 Jun) 96 (6) 589-92;
quiz 593-4. Ref: 48
Journal code: H6F. ISSN: 0002-8223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199610

L8 ANSWER 25 OF 50 MEDLINE
AN 96122145 MEDLINE
DN 96122145
TI Exercise and the neurobiological control of food intake and energy expenditure.
AU Richard D
CS Department of Physiology, Faculty of Medicine, Laval University, Sainte-Foy, Quebec, Canada.
SO INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS, (1995
Oct) 19 Suppl 4 S73-9. Ref: 78
Journal code: BTX.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199605

L8 ANSWER 26 OF 50 MEDLINE
AN 95297398 MEDLINE
DN 95297398
TI ***Obesity*** : a move from traditional to more patient-oriented management [see comments].
CM Comment in: J Am Board Fam Pract 1995 Sep-Oct;8(5):426; discussion 427-8
Comment in: J Am Board Fam Pract 1995 Sep-Oct;8(5):426-7; discussion 427-8
AU Robinson B E; Gjerdingen D K; Houge D R
CS Department of Family Practice & Community Health, University of Minnesota
Medical School, Minneapolis 55454, USA.
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, (1995 Mar-Apr) 8 (2)
99-108. Ref: 75
Journal code: 127. ISSN: 0893-8652.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199509

L8 ANSWER 27 OF 50 MEDLINE
AN 94351134 MEDLINE
DN 94351134
TI Diabetes mellitus--a priority health care issue for women.
AU Tinker L F
CS Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98104..
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1994 Sep) 94 (9) 976-85.
Ref: 102
Journal code: H6F. ISSN: 0002-8223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199412

L8 ANSWER 28 OF 50 MEDLINE
AN 94333271 MEDLINE
DN 94333271
TI Consequences of dieting to lose weight: effects on physical and mental health.
AU French S A; Jeffery R W
CS Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454-1015.
NC HL34740 (NHLBI)
SO HEALTH PSYCHOLOGY, (1994 May) 13 (3) 195-212. Ref: 190
Journal code: EJL. ISSN: 0278-6133.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199411

L8 ANSWER 29 OF 50 MEDLINE
AN 94305513 MEDLINE
DN 94305513
TI ***Review*** of nocturnal sleep-related ***eating*** disorders.
AU Schenck C H; Mahowald M W
CS University of Minnesota Medical School, Minneapolis.
SO INTERNATIONAL JOURNAL OF EATING DISORDERS, (1994 May) 15 (4) 343-56. Ref:
42
Journal code: BRF. ISSN: 0276-3478.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199410

=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		10.88	11.03

STN INTERNATIONAL LOGOFF AT 10:15:58 ON 14 SEP 2000